

# CURRICULUM VITAE

di

VINCENZO FORMICA



## INFORMAZIONI PERSONALI

Nome **VINCENZO FORMICA**  
E-mail [v.formica1@gmail.com](mailto:v.formica1@gmail.com) oppure [vincenzo.formica@pz.omceo.it](mailto:vincenzo.formica@pz.omceo.it)

Nazionalità Italiana

Data di nascita 12-12-1976

## ESPERIENZA LAVORATIVA

- 2021-oggi** **Dirigente Medico a tempo indeterminato** presso l'Unità Operativa di Oncologia Medica - Policlinico Tor Vergata – Roma (vincitore di concorso pubblico per titoli ed esami per dirigente medico-disciplina oncologia-Viterbo, deliberazione n.450 del 4/3/2021): *attività di reparto, day hospital, consulenze, tumor board, ricerca clinica e traslazionale*
- 2018-oggi** **Co-responsabile per AIOM del progetto 'Tumore è Vero Che'** – <https://www.tumoremaeveroche.it/comitato-scientifico/>
- 2014-oggi** **Co-responsabile PDTA del tumore del colon retto** e dell'analisi degli indicatori presso il Policlinico Universitario Tor Vergata di Roma. Istituzione affidante la responsabilità: Policlinico Universitario Tor Vergata di Roma
- 2006-2021** **Oncologo Medico Specialista – contratto a tempo indeterminato ACN**  
Policlinico Tor Vergata – Roma: *attività di reparto, day hospital, consulenze, tumor board, ricerca clinica e traslazionale*
- 2012-2018** **Consigliere nel consiglio direttivo di S.I.C.O.G.** (Southern Italy Cooperative Oncology Group): gruppo cooperativo per la conduzione di trial clinici multicentrici, promozione di attività scientifica, produzione di pubblicazioni scientifiche.
- 2017** **Abilitazione professore di seconda fascia 06/D3 ASN:** Abilitazione Scientifica Nazionale alle funzioni di professore di seconda fascia, nel settore concorsuale 06/D3, conseguita in data 06/04/2017 (Primo Quadrimestre 2016)
- 2013-2017** **Giornalista scientifico** nel progetto "ONCOLOGY CHANNEL: live from ESMO" a cura della società Clinical Forum S.r.l.
- 2012** **Assegnazione di Borsa di Studio** per la ricerca dal titolo: "transmembrane proteases at the interface of metabolic cues and macrovascular complications of diabetes". Istituzione affidante la Borsa: Università Tor Vergata di Roma - Dipartimento Medicina Interna
- 2009** **Responsabile progetto di ricerca** in Riabilitazione Neuro-oncologica. Istituzione affidante la ricerca: IRCCS San Raffaele Pisana di Roma.
- 2006** **Contratto a Progetto** per il progetto MEDICAL CARE CONTINUITY, progetto sostenuto dalla Commissione Europea e da eTEN programme
- 2005-2006** **Responsabile progetto di ricerca presso il Royal Marsden Hospital – Londra – Regno Unito** sui tumori neuroendocrini del tratto gastroenteropancreatico. Attività di oncologo medico specialista – fellowship per ricerca clinica sui tumori dell'apparato gastrointestinale

## ISTRUZIONE E FORMAZIONE

- 2015** **PhD in Fisiopatologia Sperimentale e Medicina Molecolare** – European label c/o Università di Roma Tor Vergata
- 2005** **Specializzazione in Oncologia Medica** c/o Università di Roma Tor Vergata – 50/50 e lode.  
*Percorso formativo: 2 anni di ricerca pre-clinica presso il laboratorio di farmacologia Università di Roma 'Tor Vergata'* (Prof. E. Bonmassar), 1 anno di *assistenza clinica presso l'Istituto Europeo di Oncologia di Milano* (Prof. A. Goldhirsch), 1 anno di *assistenza clinica presso il Royal Marsden Hospital di Londra* (Prof. D. Cunningham)
- 2004** Iscrizione con pieni titoli al **'General Medical Council'** (ordine dei medici Inglese)
- 2002** **Iscrizione all'Albo dei Medici Chirurghi**
- 2002** **Abilitazione** all'esercizio della professione medica
- 2001** **Laurea** in Medicina e Chirurgia c/o Università Campus Bio-Medico di Roma – 110 e lode e menzione d'onore del curriculum
- 1995** **Diploma** di maturità classica

**CAPACITÀ E COMPETENZE  
PERSONALI**

MADRELINGUA

ITALIANA

ALTRE LINGUE

**INGLESE**

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Ottimo (C2)

Ottimo (C2)

Ottimo (C1)

**CAPACITÀ E COMPETENZE  
TECNICHE PECULIARI**

**CAPACITÀ DI ESEGUIRE AUTONOMAMENTE TUTTE LE PRINCIPALI ANALISI BIOSTATISTICHE CON SOFTWARE AVANZATI QUALI R 4.0.2, TRA CUI:**

- ANALISI DI SOPRAVVIVENZA
- REGRESSIONE MULTIVARIATA DI COX
- REGRESSIONE LOGISTICA MULTIVARIATA
- TECNICA LASSO (LEAST ABSOLUTE SHRINKAGE AND SELECTION OPERATOR)
- DEFINIZIONE DI NOMOGRAMMI MULTIVARIATI
- CURVE DI CALIBRAZIONE
- DECISION CURVE ANALYSIS
- PROPENSITY SCORE MATCHING
- META-ANALISI

**CAPACITÀ DI ESEGUIRE AUTONOMAMENTE TUTTE LE PRINCIPALI METODICHE DI LABORATORIO PER LA RICERCA PRE-CLINICA, TRA CUI:**

- CITOFLUORIMETRIA
- WESTERN BLOT
- REAL-TIME PCR
- ELISA
- COLTURE CELLULARI
- ISOLAMENTO LINFOCITI CIRCOLANTI

**Study Coordinator** nella conduzione di Review e Meta-analisi prospettica dal titolo “Systematic review and meta-analysis for the identification of subgroups at higher chance of benefitting from immune-checkpoint inhibitors in gastric, gastro-oesophageal or oesophageal cancer”. Vincenzo Formica, Hendrik-Tobias Arkenau, Elizabeth Smyth, Elisa Fontana, Cristina Morelli.

Registrazione presso *PROSPERO (International prospective register of systematic reviews – National Institute for Health Research - UK) 2021*

CRD42021216304 (Available from:

[https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42021216304](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021216304))

**Study Coordinator** per lo studio “Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01533740) NCT01533740

**Study Coordinator** per lo studio “Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients (BMI-QoL)” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03873064) NCT03873064

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “CodeBreaK 300: A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT05198934) NCT05198934

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04607668) NCT04607668

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting (IROCAS). A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02967289) NCT02967289

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “Panitumumab REchallenge Followed by Regorafenib Versus the Reverse Sequence (PARERE). Randomized phase II study of Panitumumab REchallenge followed by Regorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients.” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04787341) NCT04787341

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT05031975) NCT05031975

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03944252) NCT03944252

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “Folfini/afllbercept in Metastatic colorectal Cancer patients With RAS Validated Wild type Status (DISTINCTIVE)” - [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04252456) NCT04252456

**Local Principal Investigator** per il centro Policlinico Tor Vergata dello studio clinico: “Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial (ARMANI)” - clinicaltrial.gov NCT02934464

**Co-ricercatore** nel progetto finanziato PRIN 2008 dal titolo “Studio di terapia Immuno-chemio-antiangiogenetica in pazienti affetti da cancro coloretale metastatico: potenziamento dell'immunità antitumorale dell'ospite in corso di trattamento multitargeting”. Coordinatore Prof. Angelo Aquino, Università degli Studi di ROMA "Tor Vergata"

**Co-ricercatore** nel progetto d'Ateneo, FINANZIAMENTI AGGIUNTIVI ATENE0 2007, dal titolo “Studio di terapia Immuno-chemio-antiangiogenetica in pazienti affetti da cancro coloretale metastatico: potenziamento dell'immunità antitumorale dell'ospite in corso di trattamento multitargeting”. Coordinatore Prof. Enzo Bonmassar, Università degli Studi di ROMA "Tor Vergata"

**Responsabile ricerca presso Royal Marsden Hospital – London –UK** 2005-2006: conduzione di ricerca sperimentale clinica sui tumori del tratto gastrointestinale ed in particolare sulla valutazione di indicatori prognostici in tumori neuroendocrini

#### ATTIVITÀ DIDATTICA IN UNIVERSITÀ ITALIANE

**Co-docente** della materia ‘oncologia medica’ nell’ambito del Corso di Laurea triennale in Tecniche Diagnostiche di Laboratorio Biomedico, negli aa 2006-2010. Università degli Studi di Roma “Tor Vergata”

**Co-docente e tutor** nell’ambito della Scuola di Specializzazione in Oncologia Medica – Università degli Studi di Roma “Tor Vergata” - aa 2015-2022

**Docente** della materia ‘oncologia medica’ nell’ambito del Corso di Laurea in Medicina e Chirurgia in lingua inglese: Medicine and Surgery – Università degli Studi di Roma “Tor Vergata” - aa 2018-2022 (titolare di CFU)

**Docente** della materia ‘oncologia medica’ nell’ambito del Corso di Laurea in Medicina e Chirurgia in lingua italiana – Università degli Studi di Roma “Tor Vergata” - aa 2021-2022 (titolare di CFU)

**Co-docente** nell’ambito del Master di II° livello in Chirurgia Epatobiliopancreatica presso l’Università degli Studi di Roma “Tor Vergata” - aa 2021-2022

**Co-docente** nell’ambito del Master di II° livello in Immuno-oncologia presso l’Università "Sapienza" di Roma - aa 2021-2022

**Invited Lecturer.** Lezione presso L’UNIVERSITÀ’ DEGLI STUDI DI PERUGIA - Dipartimento di Chimica e Tecnologia del Farmaco – titolo della lezione: “Cutting Edge: Molecular pathways of antitumor immunity. Possible therapeutic targets of pharmacological intervention”. 21 giugno 2013 - Perugia.

#### ATTIVITÀ DIDATTICA IN UNIVERSITÀ STRANIERE

**Co-docente** della materia ‘oncologia medica’ nell’ambito del Corso di Laurea Triennale in Infermeristica presso la Facoltà di Medicina dell’Università Cattolica “Nostra Signora del Buon Consiglio” – Tirana – ALBANIA - aa 2021-2022

Metrics overview su Scopus al 26/11/2022			
h-index (Hirsch index)	Citations	N. medio di citazioni per pubblicazione	Citations by
24	1608	16.24	1525 documents

N. pubblicazioni e Impact Factor da Pubmed, Web of Science e Scopus al 26/11/2022				
N.totale pubblicazioni	N. pubblicazioni su pubmed	IF totale	IF medio	
166	99	3346	20.9 (inclusi abs)	8.02 (esclusi abs)

(dalla più recente alla meno recente):

- [1] Morelli C, **Formica V**, Doldo E, Riondino S, Rofei M, Vergilii L, Palmieri G, Arkenau HT, Roselli M, Orlandi A.;Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping. *Oncologist*. 2022 May 6;27(5):e420-e421. doi: 10.1093/oncolo/oyac057. **IF 5.837**
- [2] Troncone E, Gadaleta F, Paoluzi OA, Gesuale CM, **Formica V**, Morelli C, Roselli M, Savino L, Palmieri G, Monteleone G, Del Vecchio Blanco G.;Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. *Cancers (Basel)*. 2022 Mar 29;14(7):1730. doi: 10.3390/cancers14071730. **IF 6.575**
- [3] Morelli C, Rofei M, Riondino S, Fraboni D, Torino F, Orlandi A, Tesauro M, Del Vecchio Blanco G, Federici M, Arkenau HT, **Formica V**, Roselli M.;Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation. *Cancers (Basel)*. 2022 May 24;14(11):2594. doi: 10.3390/cancers14112594. **IF 6.575**
- [4] Di Grazia A, Di Fusco D, Franzè E, Colella M, Strimpakos G, Salvatori S, **Formica V**, Laudisi F, Maresca C, Colantoni A, Ortenzi A, Stolfi C, Monteleone I, Monteleone G.;Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial-Mesenchymal Transition and Correlates with Progression of the Disease. *Cancers (Basel)*. 2022 Oct 27;14(21):5294. doi: 10.3390/cancers14215294. **IF 6.575**
- [5] Guida AM, Sensi B, **Formica V**, D'Angelillo RM, Roselli M, Del Vecchio Blanco G, Rossi P, Capolupo GT, Caricato M, Sica GS.;Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. *Biol Direct*. 2022 Jun 13;17(1):16. doi: 10.1186/s13062-022-00329-7. **IF 7.173**
- [6] Morelli C, **Formica V**, Roselli M, Arkenau HT.;Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer. *Gastric Cancer*. 2022 Nov;25(6):1123-1124. doi: 10.1007/s10120-022-01320-x. Epub 2022 Jul 2. **IF 7.701**

- [7] **Formica V**, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, Roselli M.;KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis. *J Natl Cancer Inst*. 2022 Apr 11;114(4):517-527. doi: 10.1093/jnci/djab190. **IF 11.816**
- [8] Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, **Formica V**, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C.;Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. *J Clin Oncol*. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6. **IF 50.739**
- [9] Morelli C, **Formica V**, Patrikidou A, Rofei M, Shiu KK, Riondino S, Argirò R, Floris R, Ferlosio A, Orlandi A, Roselli M, Arkenau HT. Nutritional index for immune-checkpoint inhibitor in patients with metastatic gastro-esophageal junction/gastric cancer. *J Gastrointest Oncol*. 2022 Oct;13(5):2072-2081. doi: 10.21037/jgo-22-217.**IF 2.587**
- [10] Rosenfeld R, Riondino S, **Formica V**, Torino F, Martuscelli E, Roselli M.;MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review. *J Pers Med*. 2022 Jun 28;12(7):1059. doi: 10.3390/jpm12071059. **IF 3.508**
- [11] Prete, AA; Manca, P; Morano, F; Rasola, C; Messina, M; **Formica, V**; Corsi, DC; Cortesi, E; Frassinetti, GL; Zampino, MG; Casagrande, M; Masi, G; Ronzoni, M; Scartozzi, M; Prisciandaro, M; Bergamo, F; Vettore, V; Pietrantonio, F; Fassan, M; Lonardi, S";Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the CARACAS study. *JOURNAL OF CLINICAL ONCOLOGY*;2022;Feb-01;40;4;S;5;10.1200/JCO.2022.40.4\_suppl.005. **IF 50.739**
- [12] Rossini, D; Antoniotti, C; Lonardi, S; Pietrantonio, F; Marmorino, F; Antonuzzo, L; Boccaccino, A; Randon, G; Giommoni, E; Pozzo, C; Moretto, R; De Grandis, M; Viola, M; Passardi, A; Borelli, B; Buonadonna, A; Masi, G; **Formica, V**; Aprile, G; Boni, L; Cremolini, C";Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: Results of the phase III randomized TRIPLETE study by GONO. *ANNALS OF ONCOLOGY*;2022;JUN;33;4;O-6;S381;S381;10.1016/j.annonc.2022.04.447. **IF 51.769**
- [13] **Formica V**, Nardecchia A, Morelli C, Lucchetti J, Giuliano G, Renzi N, Gallo C, Pellegrino R, Massimiliani V, Serci C, Russo A, Patrikidou A, Arkenau HT, Maiorino L, Tesaro M, Roselli M.;Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age. *Ann Palliat Med*. 2021 Apr;10(4):4252-4261. doi: 10.21037/apm-20-2194. Epub 2021 Apr 1. **IF 1.925**
- [14] Del Vecchio Blanco G, Palmieri G, Giannarelli D, **Formica V**, Portarena I, Nardecchia A, Troncone E, Benassi M, Giudice E, Anselmo A, Tisone G, Roselli M, Monteleone G, Paoluzi OA.;Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. *Scand J Gastroenterol*. 2021 Apr;56(4):498-504. doi: 10.1080/00365521.2021.1880628. Epub 2021 Feb 4. **IF 3.027**



- [15] Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzone M, Stragliotto S, Sisani M, **Formica V**, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Bruglia M, Pillozzi S, De Vita F, Antonuzzo L.; Results of the observational prospective RealFLOT study. *BMC Cancer*. 2021 Oct 8;21(1):1086. doi: 10.1186/s12885-021-08768-7. **IF 4.638**
- [16] Morelli C, **Formica V**, Riondino S, Russo A, Ferroni P, Guadagni F, Roselli M.; Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. *Curr Med Chem*. 2021;28(16):3158-3172. doi: 10.2174/0929867327666201016124950. **IF 4.74**
- [17] Bavetta M, Silvaggio D, Campione E, Sollena P, **Formica V**, Coletta D, Graziani G, Romano MCP, Roselli M, Peris K, Bianchi L.; The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. *J Clin Med*. 2021 Jan 26;10(3):466. doi: 10.3390/jcm10030466. **IF 4.964**
- [18] Del Vecchio Blanco G, Dwairi R, Giannelli M, Palmieri G, **Formica V**, Portarena I, Grasso E, Di Iorio L, Benassi M, Giudice EA, Nardecchia A, Rossi P, Roselli M, Sica G, Monteleone G, Paoluzi OA.; Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer. *Intern Emerg Med*. 2021 Aug;16(5):1197-1206. doi: 10.1007/s11739-020-02565-z. Epub 2021 Feb 8. **IF 5.472**
- [19] **Formica V**, Morelli C, Patrikidou A, Shiu KK, Nardecchia A, Lucchetti J, Roselli M, Arkenau HT.; A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. *Crit Rev Oncol Hematol*. 2021 Jan;157:103173. doi: 10.1016/j.critrevonc.2020.103173. Epub 2020 Nov 18. **IF 6.625**
- [20] Lonardi S, Prete AA, Morano F, Messina M, **Formica V**, Corsi DC, Orciuolo C, Frassinetti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, Pietrantonio F.; Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. *J Immunother Cancer*. 2021 Nov;9(11):e002996. doi: 10.1136/jitc-2021-002996. **IF 12.485**
- [21] Syeed, Z; Forster, M; Boukovinas, I; Nutting, C; Carnell, D; Urbano, TG; Sibtain, A; Kalavrezos, N; Patel, G; Al Bakir, M; Arkenau, HT; Levva, S; Gonnet, P; Morelli, C; Guerriero, S; Rofei, M; **Formica, V**; Patrikidou, A "Development of a head and neck immune prognostic index (HN-IPI) classification for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs)" *ANNALS OF ONCOLOGY*; 2021; ;32;5;889P;S798;S798;10.1016/j.annonc.2021.08.1300. **IF 51.769**
- [22] Morelli, C; **Formica, V**; Doldo, E; Riondino, S; Rofei, M; Palmieri, G; Orlandi, A; Roselli, M "Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling" *ANNALS OF ONCOLOGY*; 2021; JUL;32;3;P-148;S149;S149;10.1016/j.annonc.2021.05.203. **IF 51.769**

- [23] Guerriero, S; Morelli, C; Rofei, M; Riondino, S; Argiro, R; Morosetti, D; Gasparrini, F; Nitti, D; Benassi, M; Di Girolamo, S; D'Angelillo, RM; **Formica, V**; Roselli, M "The sarcopenia skeletal muscle mass index (SMI) has a three-tier survival effect in HNSCC, which can be predicted by hemoglobin (Hb), lymphocytes (Ly) and creatinine (Cre). *ANNALS OF ONCOLOGY* 2021; 32;5;920P; S811;S811;10.1016/j.annonc.2021.08.1330. **IF 51.769**
- [24] Rofei, M; Morelli, C; Riondino, S; Guerriero, S; Parisi, G; Argiro, R; Nitti, D; Guadagni, F; **Formica, V**; Roselli, M "Universally adopted vitamin D deficiency cutoff of 10 ng/mL is optimal for metastatic colorectal cancer prognostication and correlated with neutrophil/lymphocyte ratio" *ANNALS OF ONCOLOGY*; 2021; JUL; 32; 3;P-162; S155;S155;10.1016/j.annonc.2021.05.217. **IF 51.769**
- [25] Rofei, M; Morelli, C; Riondino, S; Guerriero, S; Parisi, G; Braudo, S; Nitti, D; Ferroni, P; Guadagni, F; Fraboni, D; Orlandi, A; **Formica, V**; Roselli, M "Vitamin D deficiency in metastatic colorectal cancer (mCRC) worsens survival and correlates with significant peripheral inflammatory/immune cell changes" *ANNALS OF ONCOLOGY*; 2021; 32;5;492P;S574;S574;10.1016/j.annonc.2021.08.1011. **IF 51.769**
- [26] **Formica V**, Morelli C, Patrikidou A, Murias C, Butt S, Nardecchia A, Lucchetti J, Renzi N, Shiu KK, Roselli M, Arkenau HT. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors. *Target Oncol.* 2020 Jun;15(3):327-336. doi: 10.1007/s11523-020-00723-z. **IF 4.897**
- [27] **Formica V**, Lucchetti J, Doldo E, Riondino S, Morelli C, Argirò R, Renzi N, Nitti D, Nardecchia A, Dell'Aquila E, Ferroni P, Guadagni F, Palmieri G, Orlandi A, Roselli M.;Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients-The Importance of Tissue/Plasma Discordant Cases. *J Clin Med.* 2020 Dec 29;10(1):87. doi: 10.3390/jcm10010087. **IF 4.964**
- [28] **Formica V**, Minieri M, Bernardini S, Ciotti M, D'Agostini C, Roselli M, Andreoni M, Morelli C, Parisi G, Federici M, Paganelli C, Legramante JM.;Complete blood count might help to identify subjects with high probability of testing positive to SARS-CoV-2. *Clin Med (Lond).* 2020 Jul;20(4):e114-e119. doi: 10.7861/clinmed.2020-0373. Epub 2020 Jul 2. **IF 5.41**
- [29] Riondino S, Ferroni P, Del Monte G, **Formica V**, Guadagni F, Roselli M.;Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. *Cancers (Basel).* 2020 May 6;12(5):1167. doi: 10.3390/cancers12051167. **IF 6.575**
- [30] **Formica V**, Morelli C, Patrikidou A, Shiu KK, Roselli M, Arkenau HT. Lymph node-only metastatic gastric/gastroesophageal junction cancer and efficacy of immunotherapy. *Gastric Cancer.* 2020 Nov;23(6):1107-1108. doi: 10.1007/s10120-020-01084-2. Epub 2020 May 18. **IF 7.701**
- [31] Vivaldi C, Salani F, Rovesti G, Pecora I, Catanese S, Casadei-Gardini A, Massa V, Bernardini L, Riggi L, Andrikou K, Rapposelli GI, **Formica V**, Lencioni M, Falcone A, Vasile E, Fornaro L. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?. *Eur J Cancer.* 2020 Sep;137:108-116. doi: 10.1016/j.ejca.2020.06.031. Epub 2020 Aug 1. **IF 10.002**
- [32] Lonardi, S; Schirripa, M; Buggin, F; Antonuzzo, L; Merelli, B; Boscolo, G; Cinieri, S; Di Donato, S; Lobefaro, R; Moretto, R; **Formica, V**;



- Passardi, A; Ricci, V; Pella, N; Scartozzi, M; Zustovich, F; Zagonel, V; Fassan, M; Boni, L; Loupakis, F. First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. *JOURNAL OF CLINICAL ONCOLOGY*;2020;May-20;38;15;S;4002. **IF 50.739**
- [33] Morelli, C; **Formica, V**; Patrikidou, A; Murrias, C; Butt, S; Nardecchia, A; Lucchetti, J; Renzi, N; Iannantuono, GM; Roselli, M; Shiu, KK; Arkenau, T. Gastric Immune Prognostic Index (GIPI) in metastatic (m) gastro-oesophageal junction (GOJ)/gastric cancer (GC) patients (pts) treated with PD-1/PD-L1 immune checkpoint inhibitors (ICIs). *JOURNAL OF CLINICAL ONCOLOGY*;2020;Feb-01;38;4;S;417. **IF 50.739**
- [34] Morelli, C; **Formica, V**; Patrikidou, A; Murias, C; Butt, SUR; Nardecchia, A; Lucchetti, J; Renzi, N; Shiu, KK; Roselli, M; Arkenau, T. Gastric inflammatory prognostic index (GIPI) to predict efficacy of PD-1/PD-L1 immune checkpoint inhibitors in metastatic gastroesophageal junction (GOJ)/gastric cancer (GC) patients. *JOURNAL OF CLINICAL ONCOLOGY*;2020;May-20;38;15;S;4530 **IF 50.739**
- [35] Giommoni, E; De Vita, F; Pecora, I; Iachetta, F; Strippoli, A; Satolli, MA; Spallanzani, A; Puzzoni, M; Nappo, F; Sisani, M; **Formica, V**; Giovanardi, F; Pozzo, C; Prisciandaro, M; Di Donato, S; Pompella, L; Salani, F; Tirino, G; Lavacchi, D; Antonuzzo, L "Perioperative FLOT in elderly patients with resectable gastric cancer: Subgroup analysis from the observational RealFLOT study". *JOURNAL OF CLINICAL ONCOLOGY*;2020;May-20;38;15;S;4548. **IF 50.739**
- [36] Giommoni, E; De Vita, F; Pecora, I; Iachetta, F; Strippoli, A; Satolli, MA; Spallanzani, A; Puzzoni, M; Stragliotto, S; Sisani, M; **Formica, V**; Giovanardi, F; Pozzo, C; Prisciandaro, M; Di Donato, S; Petrillo, A; Catanese, S; Tirino, G; Lavacchi, D; Antonuzzo, L. Perioperative FLOT in resectable gastric cancer: Italian real-world data from the RealFLOT study. *JOURNAL OF CLINICAL ONCOLOGY*;2020;Feb-01;38;4;S;300 **IF 50.739**
- [37] Lonardi, S; Pietrantonio, F; Prete, AA; Messina, M; **Formica, V**; Corsi, DC; Cortesi, E; Frassinetti, LG; Zampino, MG; Ronzoni, M; Scartozzi, M; Casagrande, M; Conca, V; Bergamo, F; Prisciandaro, M; Intini, R; Antista, M; Paola, DB; Vettore, V; Zagonel, V "Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment" *ANNALS OF ONCOLOGY*; 2020; SEP; 31; 4; 402MO; S412; S412; 10.1016/j.annonc.2020.08.513. **IF 51.769**
- [38] Morelli, C; **Formica, V**; Patrikidou, A; Murias, C; Butt, SUR; Lucchetti, J; Renzi, N; Nitti, D; Shiu, KK; Roselli, M; Arkenau, T "NUTRitional Index for immune-checkpoint inhibitors (ICI) (NUTRICI) for patients (pts) with metastatic gastro-oesophageal junction (GOJ)/gastric cancer (GC)" *ANNALS OF ONCOLOGY*; 2020; SEP; 31; 4; 1476P; S920; S921; 10.1016/j.annonc.2020.08.1982. **IF 51.769**
- [39] Buccafusca, G; Cappuccio, F; Cordio, S; Mare, M; Bruera, G; Colombo, A; **Formica, V**; Montesarchio, V; Tonini, G; Leo, S; Antonuzzo, L; Gemma, D; Biglietto, M; Giuseppina, B; Carlomagno, C; Tralongo, P "Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population" *ANNALS OF ONCOLOGY*;2020;JUL;31;3;P-66;S110;S111;10.1016/j.annonc.2020.04.148. **IF 51.769**

- [40] Lucchetti, J; **Formica, V**; Doldo, E; Morelli, C; Vergilii, L; Nitti, D; Nardecchia, A; Renzi, N; Dell'Aquila, E; Perrone, G; Palmieri, G; Orlandi, A; Roselli, M "Value of liquid biopsy using high-affinity plasma DNA binding magnetic beads and qualitative real-time PCR for KRAS, NRAS and BRAF mutations in metastatic colorectal cancer patients" *ANNALS OF ONCOLOGY*;2020;JUL;31;3;P-217;S161;S161;10.1016/j.annonc.2020.04.299. **IF 51.769**
- [41] **Formica V.**, Morelli C., Riondino S., Renzi N., Nitti D., Di Daniele N., Roselli M., Tesaro M. Obesity and common pathways of cancer and cardiovascular disease. *Endocrine and Metabolic Science*. 2020;1;03-apr;100065;10.1016/j.endmts.2020.100065
- [42] Sibio S, Di Giorgio A, D'Ugo S, Palmieri G, Cinelli L, **Formica V**, Sensi B, Bagagli G, Di Carlo S, Bellato V, Sica GS. Histotype influences emergency presentation and prognosis in colon cancer surgery. *Langenbecks Arch Surg*. 2019 Nov;404(7):841-851. doi: 10.1007/s00423-019-01826-6. Epub 2019 Nov 23. **IF 2.895**
- [43] Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, **Formica V**, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for (V600E)BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *Eur J Cancer*. 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19. **IF 10.002**
- [44] Morelli, C; **Formica, V**; Nardecchia, A; Lucchetti, J; Tisone, G; Anselmo, A; Blanco, CD; Benassi, M; Palmieri, G; Argiro, R; Roselli, M "A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel" *ANNALS OF ONCOLOGY*; 2019;JUL;30;4;P – 211. **IF 51.769**
- [45] **Formica, V**; Nardecchia, A; Morelli, C; Lucchetti, J; Guliano, G; Renzi, N; Gallo, C; Serici, C; Pellegrino, R; Massimiliani, V; Maiorino, L; Roselli, F "A nomogram to predict poor health -related quality of life in metastatic colorectal cancer patients" *ANNALS OF ONCOLOGY*; 2019; JUL; 30; 4; P-178;10.1093/annonc/mdz155.177";**IF**;51.769
- [46] Vivaldi, C; Ugolini, C; Orsi, G; **Formica, V**; Catanese, S; Andrea, C; Andrikou, K; Doldo, E; Pecora, I; Campani, D; Bonetti, LR; Pasquini, G; Salani, F; Massa, V; Niccoli, C; Lencioni, M; Vasile, E; Gardini, AC; Fornaro, L; Fontanini, C; Cascinu, S; Falcone, A "Characterization of mismatch repair deficiency in biliary tract cancer" *ANNALS OF ONCOLOGY*;2019;JUL;30;4;P - 279;76;76. **IF 51.769**
- [47] Morelli C, **Formica V**, Pellicori S, Menghi A, Guarino MD, Perricone R, Roselli M. Chemotherapy in Patients with Hereditary Angioedema. *Anticancer Res*. 2018 Dec;38(12):6801-6807. doi: 10.21873/anticancer.13052. **IF 2.435**
- [48] Legramante JM, Pellicori S, Magrini A, Frittelli T, **Formica V**, Roselli M. Cancer Patients in the Emergency Department: A "Nightmare" that Might Become a Virtuous Clinical Pathway". *Anticancer Res*. 2018 Nov;38(11):6387-6391. doi: 10.21873/anticancer.12998. **IF 2.435**
- [49] Lucchetti J, **Formica V**, Giuliano G, Coletta D, Gargano L, Morosetti D, Sileri P, Palmieri G, Roselli M. Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and

- [50] **Formica V**, Benassi M, Del Vecchio Blanco G, Doldo E, Martano L, Portarena I, Nardecchia A, Lucchetti J, Morelli C, Giudice E, Rossi P, Anselmo A, Sileri P, Sica G, Orlandi A, Santoni R, Roselli M. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt. *Med Oncol.* 2018 May 2;35(6):83. doi: 10.1007/s12032-018-1141-4. **IF 3.738**
- [51] Cereda V, **Formica V**, Roselli M. Issues and promises of bevacizumab in prostate cancer treatment. *Expert Opin Biol Ther.* 2018 Jun;18(6):707-717. doi: 10.1080/14712598.2018.1479737. Epub 2018 May 30. **IF 5.589**
- [52] **Formica V**, Zaniboni A, Loupakis F, Roselli M.; Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?. *Int J Cancer.* 2018 Nov 15;143(10):2342-2350. doi: 10.1002/ijc.31616. Epub 2018 Aug 11. **IF 7.316**
- [53] Intini, R; Loupakis, F; Cremolini, C; Sartore-Bianchi, A; Pietrantonio, F; Pella, N; Santini, D; Rimassa, L; **Formica, V**; Calvetti, L; Salvatore, L; Antonuzzo, L; De Luca, E; Morano, F; Tosi, F; Moretto, R; Fassan, M; De Maglio, G; Zagonel, V; Di Maio, M "Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the BRAF, BeCool platform". *JOURNAL OF CLINICAL ONCOLOGY*; 2018; Feb-01; 36; 4; S; 639; 10.1200/JCO.2018.36.4\_suppl.639 **IF 50.739**
- [54] Morelli, C; **Formica, V**; Pellicori, S; Nardecchia, A; Roselli, M. Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patients. *ANNALS OF ONCOLOGY*; 2018; JUN;29;5;P – 033. **IF 51.769**
- [55] Riondino S, Guadagni F, **Formica V**, Ferroni P, Roselli M. Gender Differences in Cancer-associated Venous Thromboembolism. *Curr Med Chem.* 2017;24(24):2589-2601. doi: 10.2174/0929867323666161018144505. **IF 4.74**
- [56] Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Inca R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzzello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G ; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Collaborators: Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, **Formica V**, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferrri F, Spina L, Tambasco R, Testa A, Viscido A. "Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)" *Dig Liver Dis.* 2017 Apr;49(4):338-358. doi: 10.1016/j.dld.2017.01.141. Epub 2017 Jan 17. **IF 5.165**
- [57] **Formica V**, Ionta MT, Massidda B, Vessia G, Maiorino L, Casaretti R, Natale D, Barberis G, Filippelli G, Greco E, Blasi L, Mancarella S, Russo A, Barbato E, Lullo LD, Roselli M.; Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer. *Oncotarget.* 2017 Dec 17;9(2):2876-2886. doi:

- [58] Guadagni F, Riondino S, **Formica V**, Del Monte G, Morelli AM, Lucchetti J, Spila A, D'Alessandro R, Della-Morte D, Ferroni P, Roselli M.; Clinical significance of glyceimic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. *World J Gastroenterol*. 2017 Jul 28;23(28):5187-5195. doi: 10.3748/wjg.v23.i28.5187. **IF 5.374**
- [59] **Formica V**, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau HT, Guadagni F, Orlandi A, Roselli M. Biological and predictive role of ERCC1 polymorphisms in cancer. *Crit Rev Oncol Hematol*. 2017 Mar;111:133-143. doi: 10.1016/j.critrevonc.2017.01.016. Epub 2017 Jan 28. **IF 6.625**
- [60] **Formica, V**; Nardecchia, A; Pellegrino, R; Massimiliani, V; Donnarumma, L; Giuliano, G; Renzi, N; Mariotti, S; Portarena, I; Laudisi, A; Morelli, C; Lucchetti, J; Perrone, L; Riondino, S; Roselli, M. BMI and health-related quality of life (HR-QoL) in patients with metastatic colorectal cancer (mCRC). *JOURNAL OF CLINICAL ONCOLOGY*; 2017; Nov-01; 35; 31; S; 249; 10.1200/JCO.2017.35.31\_suppl.249 **IF 50.739**
- [61] **Formica, V**; Ionta, MT; Giacomo, V; Maiorino, L; Casaretti, R; Natale, D; Barberis, G; Filippelli, G; Greco, E; Blasi, L; Mancarella, S; Russo, A; Barbato, E; Di Lullo, L; Roselli, M. Prolonged (PI) vs short-term irinotecan (STI) administration: The Martha trial-A SICO (Southern Italy Cooperative Oncology Group) randomized phase III study in the first-line setting of metastatic colorectal cancer (mCRC) patients (pts). *JOURNAL OF CLINICAL ONCOLOGY*; 2017; May-20; 35; 15; 3552; 10.1200/JCO.2017.35.15\_suppl.3552. **IF 50.739**
- [62] Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretta M, Berenato R, **Formica V**, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. *Ann Oncol*. 2017 Mar 1;28(3):555-561. doi: 10.1093/annonc/mdw627. **IF 51.769**
- [63] Mariotti, S; **Formica, V**; Pellegrino, R; Nardecchia, A; Lucchetti, J; Morelli, AM; Laudisi, A; Morelli, C; Renzi, N; Massimiliani, V; Donnarumma, L; Riondino, S; Portarena, I; Roselli, M. Evaluation of QoL as a predictor of chemotherapy-induced toxicity. *ANNALS OF ONCOLOGY*; 2017; OCT; 28; 6; R6; 87. **IF 51.769**
- [64] Morelli, C; Formica, G; Pellicori, S; Roselli, M; **Formica, V**. Prediction of overall survival after 3 months of treatment using the NLR-over-time curve in pancreatic cancer patients. *ANNALS OF ONCOLOGY*; 2017; OCT; 28; 6; D21. **IF 51.769**
- [65] Zaniboni A, **Formica V**. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. *Cancer Chemother Pharmacol*. 2016 Aug;78(2):233-44. doi: 10.1007/s00280-016-3032-8. Epub 2016 Apr 18. **IF 3.288**
- [66] **Formica V**, Zaniboni A.; Response from Drs. Formica/Zaniboni to Dr. Milano. *Cancer Chemother Pharmacol*. 2016 Aug;78(2):247. doi: 10.1007/s00280-016-3082-y. Epub 2016 Jun 17. **IF 3.288**
- [67] **Formica V**, Morelli C, Ferroni P, Nardecchia A, Tesauro M, Pellicori S,

- Cereda V, Russo A, Riondino S, Guadagni F, Roselli M. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. *Cancer Biomark*. 2016 Sep 26;17(3):335-345. doi: 10.3233/CBM-160645. **IF 3.828**
- [68] Lisanti A, **Formica V**, Ianni F, Albertini B, Marinozzi M, Sardella R, Natalini B. Antioxidant activity of phenolic extracts from different cultivars of Italian onion (*Allium cepa*) and relative human immune cell proliferative induction. *Pharm Biol*. 2016;54(5):799-806. doi: 10.3109/13880209.2015.1080733. Epub 2015 Oct 9. **IF 3.889**
- [69] Mannisi, E; **Formica, V**; Benassi, M; Rossi, P; Portarena, I; Nardecchia, A; Martano, L; Cicchetti, S; Sileri, P; Paoluzi, OA; Giudice, E; Sica, G; Roselli, M; Santoni, R; Pallone, F; Monteleone, G; Blanco, GD "EUS PREDICTIVE FACTORS OF RECURRENCE IN PATIENTS WITH LOCAL ADVANCED RECTAL CANCER" *DIGESTIVE AND LIVER DISEASE*; 2016; Feb-24;48;2;OC.01.4;E73;E73;10.1016/S1590-8658(16)30016-0. **IF 5.165**
- [70] Blanco, GD; Paoluzi, OA; Mannisi, E; Bevivino, G; **Formica, V**; Portarena, I; Roselli, M; Francesco, P; Giovanni, M "REPETITION OR SIMULTANEOUS SAMPLING OF PRIMARY AND METASTATIC LESIONS IMPROVE DIAGNOSTIC ACCURACY OF EUS-FNA IN THE ASSESSMENT OF SUSPECTED NEOPLASTIC PANCREATIC MASS" *DIGESTIVE AND LIVER DISEASE*; 2016;Feb-24;48;2;P.03.5;E141;E141. **IF 5.165**
- [71] Ferroni P, **Formica V**, Della-Morte D, Lucchetti J, Spila A, D'Alessandro R, Riondino S, Guadagni F, Roselli M. Prognostic value of glycosylated hemoglobin in colorectal cancer. *World J Gastroenterol*. 2016 Dec 7;22(45):9984-9993. doi: 10.3748/wjg.v22.i45.9984. **IF 5.374**
- [72] Ferroni P, Riondino S, Laudisi A, Portarena I, **Formica V**, Alessandroni J, D'Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M.; Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. *Oncologist*. 2016 Sep;21(9):1041-9. doi: 10.1634/theoncologist.2015-0462. Epub 2016 Jul 7. **IF 5.837**
- [73] Ferroni P, Palmirotta R, Riondino S, De Marchis ML, Nardecchia A, **Formica V**, Guadagni F, Roselli M. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. *Thromb Haemost*. 2016 Jan;115(1):143-51. doi: 10.1160/TH15-03-0259. Epub 2015 Sep 3. **IF 6.83**
- [74] Roselli M, **Formica V**, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. *Oncoimmunology*. 2016 May 19;5(7):e1188243. doi: 10.1080/2162402X.2016.1188243. eCollection 2016 Jul. **IF 7.723**
- [75] **Formica V**, Formica D, Formica G. The 'death pace' in the CO.17 trial. *Eur J Cancer*. 2016 Jan;53:1-4. doi: 10.1016/j.ejca.2015.09.020. Epub 2015 Dec 11. **IF 10.002**
- [76] Moschetta, M; Kasenda, B; Mak, G; Voskoboynik, M; Martynyuk, N; **Formica, V**; Rafii, S; Arkenau, HT "Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors" *JOURNAL OF CLINICAL ONCOLOGY*; 2016; May-20; 34; 15; S; e14513; 10.1200/JCO.2016.34.15\_suppl.e14513. **IF 50.739**
- [77] Moschetta, M; Kasenda, B; Mak, G; Voskoboynik, M; Martynyuk, N;



- Rafii, S; **Formica, V**; Arkenau, HT "Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition" *ANNALS OF ONCOLOGY*; 2016; Oct-01; 27; 6; 80P; 10.1093/annonc/mdw363.28. **IF 51.769**
- [78] Fiaschetti V, Liberto V, Claroni G, Loreni G, **Formica V**, Roselli M, Mauriello A, Floris R. Relevance of computed tomography and magnetic resonance imaging for penile metastasis after prostatectomy: uncommon case report and brief review of the literature. *Radiol Case Rep*. 2016 May 14;11(3):255-9. doi: 10.1016/j.radcr.2016.04.003. eCollection 2016 Sep.
- [79] Del Vecchio Blanco G, Coppola M, Mannisi E, Bevivino G, **Formica V**, Portarena I, Romeo S, Sileri P, Roselli M, Pallone F, Paoluzi OA. Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass. *Eur J Gastroenterol Hepatol*. 2015 Sep;27(9):1045-51. doi: 10.1097/MEG.0000000000000390. **IF 2.586**
- [80] Riondino S, Ferroni P, Spila A, Alessandroni J, D'Alessandro R, **Formica V**, Della-Morte D, Palmirota R, Nanni U, Roselli M, Guadagni F. Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle. *Cancer Genomics Proteomics*. 2015 Nov-Dec;12(6):291-9. **IF 3.395**
- [81] **Formica V**, Montefusco E, Roselli M. Are there alternative ways to quantify the real benefit of novel agents in oncology? - the 'death pace'. *Cancer Biol Ther*. 2015;16(2):187-8. doi: 10.1080/15384047.2014.1002368. **IF 4.875**
- [82] **Formica V**, Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer. *World J Gastroenterol*. 2015 Mar 14;21(10):2871-4. doi: 10.3748/wjg.v21.i10.2871. **IF 5.374**
- [83] Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, **Formica V**, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist*. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7. **IF 5.837**
- [84] Cereda V, **Formica V**, Menghi A, Pellicori S, Roselli M. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges. *Expert Opin Investig Drugs*. 2015;24(7):929-47. doi: 10.1517/13543784.2015.1035708. Epub 2015 Apr 9. **IF 6.498**
- [85] Ferroni P, Riondino S, **Formica V**, Cereda V, Tosetto L, La Farina F, Valente MG, Vergati M, Guadagni F, Roselli M. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. *Int J Cancer*. 2015 Mar 1;136(5):1234-40. doi: 10.1002/ijc.29076. Epub 2014 Jul 23. **IF 7.316**
- [86] **Formica, V**; Pellicori, S; Arkenau, HT; Morelli, C; Lucchetti, J; Nardecchia, A; Riondino, S; Ferroni, P; Cereda, V; Tesauro, M; Guadagni, F; Roselli, M "Ideal Body Mass Index (BMI) is significantly different between curatively resected and metastatic colorectal cancer (CRC) patients on chemotherapy" *EUROPEAN JOURNAL OF CANCER*;2015;SEP;51;3;1571;S228;S228;10.1016/S0959-8049(16)30660-8. **IF 10.002**



- [87] Giordano, G; Febbraro, A; Vaccaro, V; Zagonel, V; De Giorgi, U; Melisi, D; Vasile, E; Bianco, R; Lo Re, G; Valente, M; **Formica, V**; Montesarchio, V; Maiorino, L; Sanna, G; Bittoni, A; Ricci, V; Santini, D; Zaniboni, A; Milella, M; De Vita, F "Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian real life study" *EUROPEAN JOURNAL OF CANCER*; 2015; SEP; 51; 3; 2334; S444; 10.1016/S0959-8049(16)31250-3. **IF 10.002**
- [88] **Formica, V**; Pellicori, S; Arkenau, HT; Morelli, C; Lucchetti, J; Nardecchia, A; Riondino, S; Ferroni, P; Cereda, V; Roselli, M "Ideal Body Mass Index (BMI) difference between curatively resected and metastatic colorectal cancer (CRC) patients on chemotherapy" *JOURNAL OF CLINICAL ONCOLOGY*; 2015; May-20; 33; 15; S; e20675. **IF 50.739**
- [89] Casaretti, R; Comella, P; Carlomagno, C; Maiorino, L; Greco, E; Russo, A; Sanna, G; Barzelloni, ML; Massidda, B; **Formica, V**; Serci, C; Defraia, S; Palmieri, G; Ionta, MT "A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix (R)) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICO trial 0802" *ANNALS OF ONCOLOGY*; 2015; OCT; 26; 6; L08; 92; 93. **IF 51.769**
- [90] Schirru, M; **Formica, V**; Massimiliani, V; Pellegrino, R; Lucchetti, J; Antonetti, FR; Pellicori, S; Riondino, S; Roselli, M "Body Mass Index (BMI) e quality of life (QoL) in cancer patients - the 'Tor Vergata' Observational study in oNCOlogy-TV-ONCO study" *ANNALS OF ONCOLOGY*; 2015; OCT; 26; 6; P04; 124; 124. **IF 51.769**
- [91] Morelli, C; **Formica, V**; Guarino, MD; Cereda, V; Krasniqi, E; Martano, L; Menghi, A; Morelli, AM; Pellicori, S; Perricone, R; Roselli, M "Chemotherapy delivery in patients with hereditary angioedema" *ANNALS OF ONCOLOGY*; 2015; OCT; 26; 6; E35; 47; 47 **IF 51.769**
- [92] **Formica, V**; Martano, L; Nardecchia, A; Benassi, M; Blanco, GD; Giudice, E; Mannisi, E; Sileri, P; Franceschilli, L; Rossi, P; Portarena, I; Pellicori, S; Krasniqi, E; Adamo, R; Riondino, S; Santoni, R; Roselli, M "Cisplatin plus capecitabine (CisCape) and concurrent pelvic radiotherapy for the neoadjuvant treatment of rectal cancer (RC)" *ANNALS OF ONCOLOGY*; 2015; OCT; 26; 6; E44; 49; 49. **IF 51.769**
- [93] **Formica, V**; Martano, L; Nardecchia, A; Portarena, I; Benassi, M; Giudice, E; Blanco, GD; Mannisi, E; Franceschilli, L; Sileri, P; Roselli, M "Cisplatin plus capecitabine (CisCape) and radiotherapy (RT) for the neoadjuvant treatment of rectal cancer: final update of previously reported data" *ANNALS OF ONCOLOGY*; 2015; JUN; 26; 4; P-323; 10.1093/annonc/mdv233.319. **IF 51.769**
- [94] Krasniqi E, Pellicori S, **Formica V**.; Emerging role of S-1 in gastric cancer. *Indian J Med Paediatr Oncol*. 2015 Oct-Dec; 36(4):219-28. doi: 10.4103/0971-5851.171542.
- [95] Ferroni P, Roselli M, Portarena I, **Formica V**, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirota R, Guadagni F. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. *Anticancer Res*. 2014 Mar; 34(3):1153-61. **IF 2.435**
- [96] **Formica V**, Lucchetti J, Cunningham D, Smyth EC, Ferroni P, Nardecchia A, Tesaro M, Cereda V, Guadagni F, Roselli M. Systemic

inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. *Med Oncol*. 2014 Sep;31(9):166. doi: 10.1007/s12032-014-0166-6. Epub 2014 Aug 23. **IF 3.738**

- [97] Mannisi, E; Bevivino, G; Coppola, M; Romeo, S; Paoluzi, OA; **Formica, V**; Portarena, I; Sileri, P; Pallone, F; Blanco, GD "CLINICAL IMPACT OF EUS-FNA ON DIAGNOSTIC WORK UP AND THERAPEUTIC DECISION IN PATIENTS WITH SUSPICION OF MALIGNANT LESIONS" *DIGESTIVE AND LIVER DISEASE*; 2014; MAR; 46; 2; P.03.8; S62; 10.1016/S1590-8658(14)60182-1. **IF 5.165**
- [98] **Formica V**, Cereda V, Nardecchia A, Tesauro M, Roselli M. Immune reaction and colorectal cancer: friends or foes? *World J Gastroenterol*. 2014 Sep 21;20(35):12407-19. doi: 10.3748/wjg.v20.i35.12407. **IF 5.374**
- [99] Cereda V, **Formica V**, Massimiani G, Tosetto L, Roselli M. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. *Expert Opin Investig Drugs*. 2014 Apr;23(4):469-87. doi: 10.1517/13543784.2014.885950. Epub 2014 Feb 3. **IF 6.498**
- [100] **Vincenzo Formica**, Manfredi Tesauro, Carmine Cardillo, Mario Roselli. CD26: a multi-purpose pharmacological target. *Curr Clin Pharmacol*. 2014 May;9(2):157-64. doi: 10.2174/157488470866613111201654.
- [101] **Formica V**, Cereda V, di Bari MG, Grenga I, Tesauro M, Raffaele P, Ferroni P, Guadagni F, Roselli M. Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). *Med Oncol*. 2013 Dec;30(4):743. doi: 10.1007/s12032-013-0743-0. Epub 2013 Oct 11. **IF 3.738**
- [102] Roselli M, Cereda V, di Bari MG, **Formica V**, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. *Oncoimmunology*. 2013 Oct 1;2(10):e27025. doi: 10.4161/onci.27025. **IF 7.723**
- [103] **Formica, V**; Cereda, V; Di Bari, MG; Grenga, I; Tesauro, M; Palmirota, R; Ferroni, R; Guadagni, F; Roselli, M "Peripheral CD45RO, PD1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab/5FU/irinotecan (B-FOLFIRI)" *EUROPEAN JOURNAL OF CANCER*;2013;SEP;49;2;2433;S570;S570. **IF 10.002**
- [104] Roselli M, Ferroni P, Rolfo C, Peeters M, Palmirota R, **Formica V**, Ludovici G, Laudisi A, De Marchis ML, La Farina F, Russo A, Guadagni F. TNF-alpha gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. *Ann Oncol*. 2013 Oct;24(10):2571-2575. doi: 10.1093/annonc/mdt251. Epub 2013 Jul 12. **IF 51.769**
- [105] Palmirota R, Ludovici G, De Marchis ML, Leone B, **Formica V**, Ettore GM, Cavaliere F, Della-Morte D, Ferroni P, Roselli M, Guadagni F. A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. *In Vivo*. 2012 Jul-Aug;26(4):537-47. **IF 2.406**
- [106] Ferroni P, Riondino S, Portarena I, **Formica V**, La Farina F, Martini F, Massimiani G, Palmirota R, Guadagni F, Roselli M. Association between increased tumor necrosis factor alpha levels and acquired

activated protein C resistance in patients with metastatic colorectal cancer. *Int J Colorectal Dis*. 2012 Dec;27(12):1561-7. doi: 10.1007/s00384-012-1493-8. Epub 2012 May 12. **IF 2.796**

- [107] **Formica V**, Tesauro M, Cardillo C, Roselli M. Insulinemia and the risk of breast cancer and its relapse. *Diabetes Obes Metab*. 2012 Dec;14(12):1073-80. doi: 10.1111/j.1463-1326.2012.01614.x. Epub 2012 May 17. **IF 6.408**
- [108] Roselli M, Ferroni P, Portarena I, Riondino S, La Farina F, **Formica V**, Vergati M, Guadagni F. Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients. *Thromb Haemost*. 2012 Dec;108(6):1243-5. doi: 10.1160/TH12-06-0418. Epub 2012 Oct 10. **IF 6.83**
- [109] Ferroni, P; Portarena, I; La Farina, F; Massimiani, G; Riondino, S; Martini, F; Mariotti, S; **Formica, V**; Guadagni, F; Roselli, M "Novel High-sensitive D-dimer Determination Predicts Chemotherapy-associated Venous Thromboembolism in Cancer Patients" *EUROPEAN JOURNAL OF CANCER*; 2012; JUL; 48; 5; 799; S190; 10.1016/S0959-8049(12)71432-6. **IF 10.002**
- [110] Sileri, P; D' Ugo, S; Angelucci, GP; Franceschilli, L; D'Eletto, M; Capperucci, M; **Formica, V**; Palmieri, G; Di Lorenzo, N; Gaspari, A "Role of Metastatic Lymph Node Ratio as a Prognostic Index in Colorectal Cancer Surgery" *GASTROENTEROLOGY*; 2012; MAY; 142;5;1;S1073. **IF 33.883**
- [111] **Formica V**, Vasile E, Roselli M. Family history of cancer in patients with gastric cancer. *J Clin Oncol*. 2012 Sep 1;30(25):3151-2; author reply 3152-3. doi: 10.1200/JCO.2012.43.1957. Epub 2012 Jul 23. **IF 50.739**
- [112] Cossignani, M; Caruso, A; Coppola, M; Cretella, M; **Formica, V**; Portarena, I; Pallone, F; Blanco, GD "THE INFLUENCE OF PROGNOSTIC FACTORS ON SURVIVAL IN PATIENTS WITH ADVANCED PANCREATIC CANCER EVALUATED IN NOT REFERRED CENTRE" *ANNALS OF ONCOLOGY*; 2012; JUN; 23; 4; 63. **IF 51.769**
- [113] Sileri P, D'Ugo S, Del Vecchio Blanco G, Lolli E, Franceschilli L, **Formica V**, Anemona L, De Luca C, Gaspari AL. Solitary metachronous gastric metastasis from pulmonary adenocarcinoma: Report of a case. *Int J Surg Case Rep*. 2012;3(8):385-8. doi: 10.1016/j.ijscr.2012.04.017. Epub 2012 May 8.
- [114] **Formica V**, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F, Roselli M. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. *Int J Colorectal Dis*. 2011 Feb;26(2):143-51. doi: 10.1007/s00384-010-1108-1. Epub 2010 Dec 29. **IF 2.796**
- [115] **Formica V**, Del Monte G, Giacchetti I, Grenga I, Giaquinto S, Fini M, Roselli M. Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience. *Integr Cancer Ther*. 2011 Jun;10(2):119-26. doi: 10.1177/1534735410392575. Epub 2010 Dec 31. **IF 3.077**
- [116] Sileri, P; **Formica, V**; Angelucci, G; Franceschilli, L; D'Ugo, S; Capperucci, M; Gentileschi, P; Di Lorenzo, N; Picone, E; Gaspari, A "ADHESIONAL SMALL BOWEL OBSTRUCTION AFTER OPEN

AND LAPAROSCOPIC COLORECTAL SURGERY: A PROSPECTIVE LONGER-TERM STUDY" *DISEASES OF THE COLON & RECTUM*; 2011;MAY;54;5;E185;E185. **IF 4.657**

- [117] Caruso, A; Cossignani, M; Cretella, M; Coppola, M; Mannisi, E; **Formica, V** "CONTRAST-ENHANCED ULTRASONOGRAPHY IN EARLY ASSESSMENT OF THE EFFICACY OF CHEMOTHERAPY IN PATIENTS WITH LIVER METASTASIS: A PRELIMINARY REPORT" *ANNALS OF ONCOLOGY*; 2011; JUN; 22; 5; v68. **IF 51.769**
- [118] Caruso, A; Cretella, M; Cossignani, M; Coppola, M; Mannisi, E; Sileri, P; **Formica, V**; Portarena, I; Roselli, M; Pallone, F; Blanco, GD "EUS ACCURACY IN RESTAGING RECTAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY: A PRELIMINARY REPORT" *DIGESTIVE AND LIVER DISEASE*; 2010; MAR; 42; 2; P.108; S141;S141;10.1016/S1590-8658(10)60221-6. **IF 5.165**
- [119] **Formica, V**; Grenga, I; Tesauro, M; Cereda, V; di Bari, MG; Guadagni, F; Roselli, M "Metabolic Syndrome (MetS) in Metastatic (m) Colorectal Cancer (CRC) Patients (pts) Might Delay the Onset of Cachexia" *EUROPEAN JOURNAL OF CANCER*; 2011; SEP; 47; 1; S241; S241; 10.1016/S0959-8049(11)71136-4" **IF 10.002**
- [120] Sileri, P; D' Ugo, S; Franceschilli, L; Angelucci, GP; Capperucci, M; Picone, E; Gentileschi, P; Di Lorenzo, N; **Formica, V**; Roselli, M; Gaspari, A "Adhesional Small Bowel Obstruction After Open and Laparoscopic Colorectal Surgery: A Prospective Longer-Term Study" *GASTROENTEROLOGY*; 2011;MAY;140;5;1;S1029. **IF 33.883**
- [121] Sileri, P; Franceschilli, L; D'Eletto, M; Angelucci, GP; Lazzaro, S; Capperucci, M; Palmieri, G; Di Lorenzo, N; **Formica, V**; Gaspari, A "Ex-Vivo Intra-Arterial Methylene Blue Dye Injection Augments Pathology Lymph-Nodes Harvest Following Colorectal Cancer Surgery" *GASTROENTEROLOGY*;2011;MAY;140;5;1;S1004. **IF 33.883**
- [122] **Formica V**, Martano L, Palmirotta R, Ferroni P, Del Monte G, Guadagni F, Roselli M. VEGF gene polymorphisms may be associated with an increased risk of fluorouracil-induced diarrhea. *Ann Oncol.* 2011 Aug;22(8):1928-9. doi: 10.1093/annonc/mdr273. Epub 2011 May 9. **IF 51.769**
- [123] **Formica, V**; Portarena, I; Benassi, M; Fiaschetti, V; Blanco, GDV; Sileri, P; Martano, L; Guidi, C; Franceschilli, L; Pallone, F; Roselli, M "CISPLATIN YIELDS HIGH RATE OF PATHOLOGIC COMPLETE RESPONSE (ypCR) IN COMBINATION WITH CAPECITABINE AND PELVIC RADIATION IN THE NEOADJUVANT TREATMENT OF RECTAL CANCER" *ANNALS OF ONCOLOGY*; 2011; JUN; 22; 5; v122; v122. **IF 51.769**
- [124] Caruso, A; Cossignani, M; Cretella, M; Coppola, M; **Formica, V**; Portarena, I; Roselli, M; Pallone, F; Blanco, GD "CONTRAST-ENHANCED ULTRASONOGRAPHY IN EARLY ASSESSMENT OF THE EFFICACY OF CHEMOTHERAPY IN PATIENTS WITH LIVER METASTASIS: A PRELIMINARY REPORT" *DIGESTIVE AND LIVER DISEASE*; 2011;MAR;43;3;S192;S192;10.1016/S1590-8658(11)60362-9. **IF 5.165**
- [125] Pellegrino R, **Formica V**, Portarena I, Mariotti S, Grenga I, Del Monte G, Roselli M. Caregiver distress in the early phases of cancer. *Anticancer Res.* 2010 Nov;30(11):4657-63. **IF 2.435**
- [126] Bonmassar L, Fossile E, Scoppola A, Graziani G, Prete SP, **Formica V**,

Cappelletti D, De Vecchis L, Cardillo A, Concolino F, D'Atri S, Balduzzi A, Torino F, Caporaso P, Greiner JW, Bonmassar E, Roselli M, Aquino A. Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. *Anticancer Res.* 2010 Nov;30(11):4721-30. **IF 2.435**

- [127] Ferroni P, **Formica V**, Roselli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogenic drugs. *Curr Vasc Pharmacol.* 2010 Jan;8(1):102-13. doi: 10.2174/157016110790226660. **IF 3.524**
- [128] Caruso, A; Blanco, GDV; Cretella, M; Mannisi, E; **Formica, V**; Portarena, I; Sica, G; Sileri, P; Roselli, M; Gaspari, A; Pallone, F "EUS ACCURACY IN RESTAGING RECTAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY: A PRELIMINARY REPORT" *DIGESTIVE AND LIVER DISEASE*; 2011; MAR; 43; 3; S227; S228; 10.1016/S1590-8658(11)60468-4. **IF 5.165**
- [129] Caruso, A; Blanco, GD; Cretella, M; Mannisi, E; **Formica, V**; Portarena, I; Sica, GS; Sileri, P; Roselli, M; Gaspari, A; Pallone, F "EUS Accuracy in Restaging Rectal Cancer After Neoadjuvant Chemoradiotherapy: A Preliminary Report" *GASTROENTEROLOGY*; 2010; MAY; 138; 5; 1; W1154; S663. **IF 33.883**
- [130] Squadroni, M; Di Meglio, G; Spada, F; Terzi, S; Lorizzo, K; De Braud, FG; **Formica, V**; Goldhirsch, A; Fazio, N "Metronomic capecitabine in advanced well or moderately differentiated neuroendocrine carcinomas" *JOURNAL OF CLINICAL ONCOLOGY*; 2010; May-20; 28; 15; S; e13130; 10.1200/jco.2010.28.15\_suppl.e13130. **IF 50.739**
- [131] Squadroni M., **Formica V.**, di Meglio G., Dealis C., Spada F., Lorizzo K., Fazio N. Pancreatic neuroendocrine tumors: A focus on the current classification and molecular targeted therapy. *European journal of Clinical and Medical Oncology* 2010;2;2
- [132] Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, **Formica V**, Laudisi A, Portarena I, Palmirota R, Ferroni P. Prognostic significance of serum adipokine levels in colorectal cancer patients. *Anticancer Res.* 2009 Aug;29(8):3321-7. **IF 2.435**
- [133] Palmirota R, Savonarola A, **Formica V**, Ludovici G, Del Monte G, Roselli M, Guadagni F. A novel K-ras mutation in colorectal cancer. A case report and literature review. *Anticancer Res.* 2009 Aug;29(8):3369-74. **IF 2.435**
- [134] **Formica V**, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. *Acta Haematol.* 2009;122(4):193-9. doi: 10.1159/000253026. Epub 2009 Oct 29. **IF 3.068**
- [135] **Formica V**, Fossile E, Pellegrino R, Fatale M, Mari M, Rabuffetti M, Benedetto FR, Visconti G, Bollero E, Roselli M. The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience. *Support Care Cancer.* 2009 May;17(5):471-8. doi: 10.1007/s00520-008-0559-1. Epub 2008 Dec 17. **IF 3.359**
- [136] **Formica V**, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. *Cancer Biomark.* 2009;5(4):167-75. doi: 10.3233/CBM-2009-0101. **IF 3.828**



- [137] **Formica, V**; Palmirotta, R; Del Monte, G; Savonarola, A; Ludovici, G; De Marchis, ML; Grenga, I; Schirru, M; Guadagni, F; Roselli, M "VEGF polymorphisms as predictors of bevacizumab efficacy in metastatic colorectal cancer" *EJC SUPPLEMENTS*; 2009; OCT; 7; 4; 17; 17; 10.1016/S1359-6349(09)72163-9. **IF 9.386**
- [138] Sileri, P; D'Ugo, S; **Formica, V**; Gentileschi, P; Stolfi, VM; Di Lorenzo, N; Angelucci, GP; Roselli, M; Gaspari, A "Access Related Complications After Open and Laparoscopic Colorectal Surgery: A Prospective Study" *GASTROENTEROLOGY*; 2009; MAY; 136; 5; 1; A910. **IF 33.883**
- [139] Palmirotta, R; Savonarola, A; **Formica, V**; Ludovici, G; D'Alessandro, R; Leone, B; Ciancia, M; Liberatore, R; D'Angelo, S; Roselli, M; Guadagni, F "A NOVEL NONSENSE MUTATION IN KRAS GENE" *ANTICANCER RESEARCH*; 2008; SEP-OCT; 28; 5C; 509; 3433. **IF 2.435**
- [140] Roselli, M; **Formica, V**; Martini, F; Portarena, I; Mariotti, S; Del Monte, G; La Farina, F; Lucci, I; D'Angelo, S; Ferroni, P; Guadagni, F "ASSOCIATION BETWEEN INFLAMMATORY MEDIATORS, D-DIMER LEVELS AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN PATIENTS WITH ADENOCARCINOMA" *ANNALS OF ONCOLOGY*; 2008; SEP; 19; 56; 57. **IF 51.769**
- [141] Guadagni, F; Roselli, M; Spila, A; D'Alessandro, R; Lucci, I; Polce, L; **Formica, V**; Laudisi, A; Portarena, I; Palmirotta, R; Ferroni, P "SERUM LEPTIN LEVELS IN COLORECTAL CANCER PATIENTS" *ANTICANCER RESEARCH*; 2008; SEP-OCT; 28; 5C; 245; 3304. **IF 2.435**
- [142] Blanco, GD; **Formica, V**; Portarena, I; Caruso, A; Mannisi, E; Massara, M; Grenga, I; Rossi, L; Pallone, F; Roselli, M "ROLE OF CIRCULATING TUMOUR MARKER CA19.9 AND ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER ON FIRST LINE SYSTEMIC TREATMENT" *DIGESTIVE AND LIVER DISEASE*; 2008; MAR; 40; 1; OC3.06.5; S53; S54. **IF 5.165**
- [143] Roselli, M; Mariotti, S; Martini, F; Portarena, I; **Formica, V**; La Farina, F; Lucci, I; D'Angelo, S; Ferroni, P; Guadagni, F "ASSOCIATION BETWEEN INFLAMMATORY MEDIATORS, D-DIMER LEVELS AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN PATIENTS WITH ADENOCARCINOMA" *ANTICANCER RESEARCH*; 2008; SEP-OCT; 28; 5C; 569; 3464; 3465. **IF 2.435**
- [144] Del Vecchio, BG; Sileri, P; **Formica, V**; Portarena, I; Flori, R; Vanni, S; Varani, S; Sica, G; Palmieri, G; Gaspari, L; Simonetti, G; Roselli, M; Pallone, F "Rectal cancer T staging: Role of endoscopic ultrasound (EUS) and computerized tomographic colonography (CTC)" *ANNALS OF ONCOLOGY*; 2008; 19; 6; 98. **IF 51.769**
- [145] **Formica, V**; Portarena, I; Fiaschetti, V; Del Vecchio, G; Massara, M; Sica, G; Sileri, P; Grenga, I; Pallone, F; Roselli, M. Role of circulating tumour marker CA 19.9 and antiangiogenic therapy with bevacizumab in patients with metastatic colorectal cancer on first line systemic treatment. *ANNALS OF ONCOLOGY*; 2008; 19; 6; 96; 97. **IF 51.769**
- [146] Guadagni F, Ferroni P, Palmirotta R, Portarena I, **Formica V**, Roselli M. Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. *In Vivo*. 2007 Mar-Apr; 21(2):147-61. **IF 2.406**



- [147] Masala S, Manenti G, Roselli M, Mammucari M, Bartolucci DA, **Formica V**, Massari F, Simonetti G. Percutaneous combined therapy for painful sternal metastases: a radiofrequency thermal ablation (RFTA) and cementoplasty protocol. *Anticancer Res.* 2007 Nov-Dec;27(6C):4259-62. **IF 2.435**
- [148] Guadagni F, Ferroni P, Palmirotta R, Del Monte G, **Formica V**, Roselli M. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. *Anticancer Res.* 2007 Sep-Oct;27(5A):3147-62. **IF 2.435**
- [149] **Formica V**, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, Chong G. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. *Br J Cancer.* 2007 Apr 23;96(8):1178-82. doi: 10.1038/sj.bjc.6603699. Epub 2007 Apr 3. **IF 9.082**
- [150] Roselli, M; **Formica, V**; Fossile, E; Pellegrino, R; Mari, M; Rabuffetti, M; Benedetto, FR; Visconti, G; Bollero, E "Feasibility and efficacy of video-assisted home care for cancer patients on chemotherapy (medical care continuity-mcc project). the preliminary Italian experience" *EJC SUPPLEMENTS*;2007;SEP;5;4;1124;149;149;10.1016/S1359-6349(07)70643-2. **IF 9.386**
- [151] Ferroni, P; Palmirotta, R; Martini, F; Ludovici, G; Magnapera, A; Rossi, L; Vergati, M; **Formica, V**; Roselli, M; Guadagni, F "Determinants of homocysteine levels in colorectal and breast cancer patients" *THROMBOSIS RESEARCH*;2007;;120;2;S146;S146;10.1016/S0049-3848(07)70158-5. **IF 10.409**
- [152] **Formica V**, Leary A, Cunningham D, Chua YJ. 5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. *Cancer Chemother Pharmacol.* 2006 Aug;58(2):276-8. doi: 10.1007/s00280-005-0159-4. Epub 2005 Dec 7. **IF 3.288**
- [153] Ferroni P, Palmirotta R, Spila A, Martini F, **Formica V**, Portarena I, Del Monte G, Buonomo O, Roselli M, Guadagni F. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. *Oncology.* 2006;71(3-4):176-84. doi: 10.1159/000106072. Epub 2007 Jul 23. **IF 3.734**
- [154] **Formica, V**; Norman, AR; Cunningham, D; Wotherspoon, A; Sirohi, B; Oates, J; Chong, G "The prognostic role of the WHO classification, urinary 5-hydroxyindoleacetic acid (u5HIAA) and liver function tests (LFTs) in metastatic neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract" *JOURNAL OF CLINICAL ONCOLOGY*;2006;Jun-20;24;18;1;S;4092;201S. **IF 50.739**
- [155] Curigliano G, **Formica V**, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F, Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. *Ann Oncol.* 2006 Jul;17(7):1174-5. doi: 10.1093/annonc/mdj126. Epub 2006 Jan 12. **IF 51.769**
- [156] Del Monte, G; Ferroni, P; Mariotti, S; Fossile, E; **Formica, V**; Palmirotta, R; Buonomo, O; Guadagni, F; Roselli, M. Correlation between vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) tissue content in colorectal cancer patients. *ANNALS OF ONCOLOGY*;2006;17;11;XI42. **IF 51.769**

- [157] De Pas T, Sbanotto A, Catania C, Banfi MG, Curigliano G, Nolè F, Fazio N, **Formica V**, Veronesi G, de Braud F. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. *Support Care Cancer*. 2005 Mar;13(3):194-5. doi: 10.1007/s00520-004-0706-2. Epub 2004 Nov 17. **IF 3.359**
- [158] Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, **Formica V**, Giorgi G, Bonmassar E, Francini G. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. *J Immunol*. 2005 Jul 15;175(2):820-8. doi: 10.4049/jimmunol.175.2.820. **IF 5.43**
- [159] De Pas T, Putzu C, Pelosi G, Curigliano G, Noverasco C, Zampino G, Fazio N, **Formica V**, Spaggiari L, de Braud F. Target-treatment and patients' selection: can we still neglect the timing of tissue collection?. *J Clin Oncol*. 2005 Sep 1;23(25):6274-5; author reply 6275-6. doi: 10.1200/JCO.2005.01.9174. **IF 50.739**
- [160] Bonmassar L, Massara MC, Cottarelli A, Aquino A, **Formica V**, Prete SP, Lacal PM, Marchetti P, Concolino F, Faraoni I, D'Atri S. Preclinical studies on detection of circulating melanoma cells in patients: telomerase as a recognition marker of malignancy. *J Chemother*. 2004 Oct;16(5):479-86. doi: 10.1179/joc.2004.16.5.479. **IF 2.385**
- [161] Curigliano G, Rigo R, Colleoni M, Braud FD, Nole F, **Formica V**, Orlando L, Cinieri S, Torrioni R, Cardillo A, Peruzzotti G, Medici M, Ardito R, Minchella I, Goldhirsch A. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. *Clin Breast Cancer*. 2004 Jun;5(2):125-30. doi: 10.3816/cbc.2004.n.016. **IF 3.078**
- [162] Aquino A, **Formica V**, Prete SP, Correale PP, Massara MC, Turriziani M, De Vecchis L, Bonmassar E. Drug-induced increase of carcinoembryonic antigen expression in cancer cells. *Pharmacol Res*. 2004 May;49(5):383-96. doi: 10.1016/j.phrs.2003.12.007. **IF 10.334**
- [163] Orlando, L; Colleoni, M; Bertolini, F; Ghisini, R; Sanna, G; **Formica, V**; Nole, F; Viale, G; Franceschelli, L; Goldhirsch, A"; Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): Results of a randomized trial in patients (pts) with advanced breast cancer (ABC). *JOURNAL OF CLINICAL ONCOLOGY*;2004;Jul-15;22;14;S;3015;198S;198S. **IF 50.739**
- [164] de Pas, T; Biffi, R; Mazzarol, G; Della Vigna, P; Travaini, L; Curigliano, G; **Formica, V**; de Braud, F"; Imatinib discontinuation in patients with metastatic gastrointestinal stromal tumors (GISTs). *ANNALS OF ONCOLOGY*;2004;15;3;201;201. **IF 51.769**
- [165] Aquino A, Prete SP, Balduzzi A, Fossile E, **Formica V**, Torino F, Bonmassar L, Di Giacomo A, Cappelletti D, Cardillo A, Graziani G.; A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report. *J Chemother*. 2002 Aug;14(4):412-6. doi: 10.1179/joc.2002.14.4.412. **IF 2.385**
- [166] Aquino A, Prete SP, Balduzzi A, **Formica V**, Fossile E, Bonmassar L, Concolino F, Bonmassar E, Graziani G.; Treatment of peripheral blood with staurosporine increases detection of circulating carcinoembryonic antigen positive tumor cells. *Int J Cancer*. 2002 Jul 1;100(1):119-21. doi: 10.1002/ijc.10438. **IF 7.316**

## PRESENTAZIONI A CONGRESSI INTERNAZIONALI

- (1) "Irinotecan is superior to oxaliplatin in KRAS-G12C-mutated (K-G12C-m) colorectal cancer (CRC) and should be preferred in combination strategies with K-G12C inhibitors." C Morelli, J Lucchetti, MA Calegari, M Rofei, S Guerriero, S Riondino, V Flaminio, G Parisi, F Lo Prinzi, G Trovato, B Vincenzi, L Salvatore, M Roselli, **V Formica**. **ESMO Congress 2022**, 9 - 13 September 2022
- (2) "Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO". Chiara Cremolini, Daniele Rossini, Sara Lonardi, Carlotta Antoniotti, Filippo Pietrantonio, Federica Marmorino, Lorenzo Antonuzzo, Alessandra Boccaccino, Giovanni Randon, Elisa Giommoni, Carmelo Pozzo, Roberto Moretto, Maria Caterina De Grandis, Massimo Giuseppe Viola, Alessandro Passardi, Angela Buonadonna, **Vincenzo Formica**, Giuseppe Aprile, Luca Boni, Gianluca Masi. **2022 ASCO Annual Meeting**
- (3) "Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: Results of the phase III randomized TRIPLETE study by GONO". D Rossini, C Antoniotti, S Lonardi, F Pietrantonio, F Marmorino, L Antonuzzo, A Boccaccino, G Randon, E Giommoni, C Pozzo, R Moretto, M De Grandis, M Viola, A Passardi, B Borelli, A Buonadonna, G Masi, **V Formica**, G Aprile, L Boni, C Cremolini. **ESMO 24th World Congress on Gastrointestinal Cancer 2022**, Barcelona, Spain, 29 June -2 July 2022
- (4) "Vitamin D deficiency in metastatic colorectal cancer (mCRC) worsens survival and correlates with significant peripheral inflammatory/immune cell changes". M Rofei, C Morelli, S Riondino, S Guerriero, G Parisi, S Braudo, D Nitti, P Ferroni, F Guadagni, D Fraboni, A Orlandi, **V Formica**, M Roselli. **ESMO Congress 2021**, 16 – 21 September 2021
- (5) "The sarcopenia skeletal muscle mass index (SMI) has a three-tier survival effect in HNSCC, which can be predicted by hemoglobin (Hb), lymphocytes (Ly) and creatinine (Cre)". S Guerriero, C Morelli, M Rofei, S Riondino, R Argirò, D Morosetti, F Gasparri, D Nitti, M Benassi, S Di Girolamo, RM D'Angelillo, **V Formica**, M Roselli. **ESMO Congress 2021**, 16 – 21 September 2021
- (6) "Development of a head and neck immune prognostic index (HN-IPI) classification for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs)". Z Syeed, M Forster, I Boukovinas, C Nutting, D Carnell, T Guerrero Urbano, A Sibtain, N Kalavrezos, G Patel, M Al Bakir, HT Arkenau, S Levva, P Gonnet, C Morelli, S Guerriero, M Rofei, **V Formica**, A Patrikidou. **ESMO Congress 2021**, 16 – 21 September 2021
- (7) "Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests

that pharmacogenetic screening could be contextual to tumour molecular profiling”. C Morelli, **V Formica**, E Doldo, S Riondino, M Rofei, G Palmieri, A Orlandi, M Roselli. **ESMO 23rd World Congress on Gastrointestinal Cancer, 2021 Virtual - 30 June - 3 July 2021**

- (8) “Universally adopted vitamin D deficiency cutoff of 10 ng/mL is optimal for metastatic colorectal cancer prognostication and correlated with neutrophil/lymphocyte ratio”. M Rofei, C Morelli, S Riondino, S Guerriero, G Parisi, R Argiró, D Nitti, F Guadagni, **V Formica**, M Roselli. **ESMO 23rd World Congress on Gastrointestinal Cancer, 2021 Virtual - 30 June - 3 July 2021**
- (9) “Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment”. S Lonardi, F Pietrantonio, AA Prete, M Messina, **V Formica**, DC Corsi, E Cortesi, LG Frassinetti, MG Zampino, M Ronzoni, M Scartozzi, M Casagrande, V Conca, F Bergamo, M Prisciandaro, R Intini, M Antista, DB Paola, V Vettore, V Zagonel. **ESMO Virtual Congress 2020, 19 – 21 September / 16 – 18 October 2020**
- (10) “NUTRitional Index for immune-checkpoint inhibitors (ICI)(NUTRICI) for patients (pts) with metastatic gastro-oesophageal junction (GOJ)/gastric cancer (GC)”. C Morelli, **V Formica**, A Patrikidou, C Murias, SUR Butt, J Lucchetti, N Renzi, D Nitti, KK Shiu, M Roselli, T Arkenau. **ESMO Virtual Congress 2020, 19 – 21 September / 16 – 18 October 2020**
- (11) “Value of liquid biopsy using high-affinity plasma DNA binding magnetic beads and qualitative real-time PCR for KRAS, NRAS and BRAF mutations in metastatic colorectal cancer patients”. J Lucchetti, **V Formica**, E Doldo, C Morelli, L Vergilii, D Nitti, A Nardecchia, N Renzi, E Dell'Aquila, G Perrone, G Palmieri, A Orlandi, M Roselli. **ESMO 22nd World Congress on Gastrointestinal Cancer, 2020 Virtual - 1 - 4 July 2020**
- (12) “Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients”. I Pecora, C Vivaldi, G Rovesti, S Catanese, F Salani, A Casadei Gardini, V Massa, L Bernardini, M Riggi, K Andrikou, I Rapposelli, **V Formica**, S Cesario, M Caccese, M Lencioni, E Vasile, A Falcone, L Fornaro. **ESMO 22nd World Congress on Gastrointestinal Cancer, 2020 Virtual - 1 - 4 July 2020**
- (13) “Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population”. G Buccafusca, F Cappuccio, S Cordio, M Mare, G Bruera, A Colombo, **V Formica**, V Montesarchio, G Tonini, S Leo, L Antonuzzo, D Gemma, M Biglietto, B Giuseppina, C Carlomagno, P Tralongo. **ESMO 22nd World Congress on Gastrointestinal Cancer, 2020 Virtual - 1 - 4 July 2020**
- (14) “Perioperative FLOT in elderly patients with resectable gastric cancer: Subgroup analysis from the observational RealFLOT study”. Elisa Giommoni, Ferdinando De Vita, Irene Pecora, Francesco Iachetta, Antonia Strippoli, Maria Antonietta Satolli, Andrea Spallanzani, Marco Puzzoni, Floriana Nappo, Michele Sisani, **Vincenzo Formica**, Filippo Giovanardi, Carmelo Pozzo, Michele Prisciandaro, Samantha Di Donato, Luca Pompella,

Francesca Salani, Giuseppe Tirino, Daniele Lavacchi, Lorenzo Antonuzzo, GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica). **2020 ASCO Annual Meeting**

- (15) “Gastric inflammatory prognostic index (GIPI) to predict efficacy of PD-1/PD-L1 immune checkpoint inhibitors in metastatic gastroesophageal junction (GOJ)/gastric cancer (GC) patients”. Cristina Morelli, **Vincenzo Formica**, Anna Patrikidou, Carmen Murias, Sabeeh-Ur-Rehman Butt, Antonella Nardecchia, Jessica Lucchetti, Nicola Renzi, Kai-Keen Shiu, Mario Roselli, Tobias Arkenau. **2020 ASCO Annual Meeting**
- (16) “First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study”. Sara Lonardi, Marta Schirripa, Federica Buggin, Lorenzo Antonuzzo, Barbara Merelli, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Riccardo Lobefaro, Roberto Moretto, **Vincenzo Formica**, Alessandro Passardi, Vincenzo Ricci, Nicoletta Pella, Mario Scartozzi, Fable Zustovich, Vittorina Zagonel, Matteo Fassan, Luca Boni, Fotios Loupakis, Gono Group. **2020 ASCO Annual Meeting**
- (17) “FACTORS INFLUENCING DIAGNOSTIC ACCURACY OF ENDOSCOPIC ULTRASOUND WITH FINE NEEDLE ASPIRATION (EUS-FNA) IN PANCREATO-BILIARY TUMORS”. E Troncone, C Cardamone, CM Gesuale, G Palmieri, **V Formica**, I Portarena, A Nardecchia, M Benassi, E Giudice, A Anselmo, L Toti, M Manzia, G Tisone, M Roselli, G Monteleone, O Paoluzi, GDV Blanco. **ESGE Days 2020**. Dublin, Ireland, 23.-25.04.2020
- (18) “Gastric Immune Prognostic Index (GIPI) in metastatic (m) gastro-oesophageal junction (GOJ)/gastric cancer (GC) patients (pts) treated with PD-1/PD-L1 immune checkpoint inhibitors (ICIs)”. Cristina Morelli, **Vincenzo Formica**, Anna Patrikidou, Carmen Murrias, Sabeeh Butt, Antonella Nardecchia, Jessica Lucchetti, Nicola Renzi, Giovanni Maria Iannantuono, Mario Roselli, Kai-Keen Shiu, Tobias Arkenau. **2020 ASCO Gastrointestinal Cancers Symposium**
- (19) “Perioperative FLOT in resectable gastric cancer: Italian real-world data from the RealFLOT study”. Elisa Giommoni, Ferdinando De Vita, Irene Pecora, Francesco Iachetta, Antonia Strippoli, Maria Antonietta Satolli, Andrea Spallanzani, Marco Puzzone, Silvia Stragliotto, Michele Sisani, **Vincenzo Formica**, Filippo Giovanardi, Carmelo Pozzo, Michele Prisciandaro, Samantha Di Donato, Angelica Petrillo, Silvia Catanese, Giuseppe Tirino, Daniele Lavacchi, Lorenzo Antonuzzo, GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica). **2020 ASCO Gastrointestinal Cancers Symposium**
- (20) “Risk estimation in 2018: the role of tissue and liquid biomarkers”. **Vincenzo Formica**. LEARNING at the LEANING Tower **2019 GONO Congress on Colorectal Cancer**
- (21) “How to deal with fake news in colorectal cancer?”. **Vincenzo Formica**. LEARNING at the LEANING Tower **2019 GONO Congress on Colorectal Cancer**
- (22) “Characterization of mismatch repair deficiency in biliary tract cancer”. Caterina Vivaldi, Clara Ugolini, Giulia Orsi, **Vincenzo Formica**, Silvia Catanese, C Andrea, Kalliopi Andrikou, Elena



Doldo, Irene Pecora, Daniela Campani, L Reggiani Bonetti, Giulia Pasquini, Francesca Salani, Valentina Massa, Cristina Niccoli, Monica Lencioni, Enrico Vasile, A Casadei Gardini, Lorenzo Fornaro, Gabriella Fontanini, Stefano Cascinu, Alfredo Falcone. **ESMO 21st World Congress on Gastrointestinal Cancer**, 03–06 July 2019, Barcelona, Spain

- (23) “A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel”. C Morelli, **V Formica**, A Nardecchia, J Lucchetti, G Tisone, A Anselmo, G Del Vecchio Blanco, M Benassi, G Palmieri, R Argiró, M Roselli. **ESMO 21st World Congress on Gastrointestinal Cancer**, 03–06 July 2019, Barcelona, Spain
- (24) “A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients”. **V Formica**, A Nardecchia, C Morelli, J Lucchetti, G Giuliano, N Renzi, C Gallo, C Serci, R Pellegrino, V Massimiliani, L Maiorino, M Roselli. **ESMO 21st World Congress on Gastrointestinal Cancer**, 03–06 July 2019, Barcelona, Spain
- (25) “Longitudinal assessment of neutrophil-to-lymphocyte ratio (NLR) from diagnosis until death reveals a biphasic trend in metastatic pancreatic adenocarcinoma patients”. Cristina Morelli, **Vincenzo Formica**, Stefania Pellicori, Antonella Nardecchia, Mario Roselli. **ESMO 20th World Congress on Gastrointestinal Cancer** 20–23 June 2018, Barcelona, Spain
- (26) “Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the “BRAF, BeCool” platform”. Rossana Intini, Fotios Loupakis, Chiara Cremolini, Andrea Sartore-Bianchi, Filippo Pietrantonio, Nicoletta Pella, Daniele Santini, Lorenza Rimassa, **Vincenzo Formica**, Lorenzo Calvetti, Lisa Salvatore, Lorenzo Antonuzzo, Emmanuele De Luca, Federica Morano, Federica Tosi, Roberto Moretto, Matteo Fassan, Giovanna De Maglio, Vittorina Zagonel, Massimo Di Maio. **2018 ASCO Gastrointestinal Cancers Symposium**
- (27) “BMI and health-related quality of life (HR-QoL) in patients with metastatic colorectal cancer (mCRC)”. **Vincenzo Formica**, Antonella Nardecchia, Rachela Pellegrino, Valentina Massimiliani, Luisa Donnarumma, Greta Giuliano, Nicola Renzi, Sabrina Mariotti, Ilaria Portarena, Anastasia Laudisi, Cristina Morelli, Jessica Lucchetti, Lorena Perrone, Silvia Riondino, Mario Roselli. **2017 ASCO Palliative and Supportive Care in Oncology Symposium**
- (28) “Prediction of overall survival after 3 months of treatment using the NLR-over-the-time curve in pancreatic cancer patients”. C Morelli, G Formica, S Pellicori, M Roselli, **V Formica**. **19th National Congress of Medical Oncology AIOM** 27–29 October 2017, Rome, Italy
- (29) “Evaluation of QoL as a predictor of chemotherapy-induced toxicity”. S Mariotti, **V Formica**, R Pellegrino, A Nardecchia, J Lucchetti, AM Morelli, A Laudisi, C Morelli, N Renzi, V Massimiliani, L Donnarumma, S Riondino, I Portarena, M Roselli. **19th National Congress of Medical Oncology AIOM** 27–29 October 2017, Rome, Italy



- (30) “The panitumumab with FOLFOX4 in metastatic gastric or gastroesophageal junction adenocarcinoma (mGA)-VEGA trial. Efficacy and safety outcomes of a phase II SICOG study”. **Vincenzo Formica**, Rossana Casaretti, Giuseppe Comella, Chiara Carlomagno, Luigi Maiorino, Ettore Greco, Anna Russo, Gianni Sanna, Luisa Barzelloni Maria, Bruno Massidda, Cristiano Serci, S Defraia, Giuseppe Palmieri, Teresa Ionta Maria. **ESMO 19th World Congress on Gastrointestinal Cancer** 28 June-1 July 2017, Barcelona, Spain
- (31) “Prolonged (PI) vs short-term irinotecan (STI) administration: The Martha trial—A SICOG (Southern Italy Cooperative Oncology Group) randomized phase III study in the first-line setting of metastatic colorectal cancer (mCRC) patients (pts)”. **Vincenzo Formica**, Maria Teresa Ionta, Vessia Giacomo, Luigi Maiorino, Rossana Casaretti, Donato Natale, Giuseppe Barberis, Gianfranco Filippelli, Ettore Greco, Livio Blasi, Sergio Mancarella, Anna Russo, Enrico Barbato, Liberato Di Lullo, Mario Roselli. **2017 ASCO Annual Meeting**
- (32) “Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition”. Michele Moschetta, Benjamin Kasenda, Gabriel Mak, Mark Voskoboynik, Nataliya Martynyuk, Saeed Rafii, **V Formica**, H-T Arkenau. **41st ESMO Congress (ESMO 2016)**, 7-11 October 2016, Copenhagen, Denmark
- (33) “Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors”. Michele Moschetta, Benjamin Kasenda, Gabriel Mak, Mark Voskoboynik, Nataliya Martynyuk, **Vincenzo Formica**, Saeed Rafii, Hendrik-Tobias Arkenau. **2016 ASCO Annual Meeting**
- (34) “REPETITION OR SIMULTANEOUS SAMPLING OF PRIMARY AND METASTATIC LESIONS IMPROVE DIAGNOSTIC ACCURACY OF EUS-FNA IN THE ASSESSMENT OF SUSPECTED NEOPLASTIC PANCREATIC MASS”. G Del Vecchio Blanco, OA Paoluzi, E Mannisi, G Bevivino, **V Formica**, I Portarena, M Roselli, P Francesco, M Giovanni. **22nd National Congress of Digestive Diseases, Italian Federation of Societies of Digestive Diseases – FISMAD**
- (35) 24 February 2016 - 27 February 2016
- (36) “Body Mass Index (BMI) e quality of life (QoL) in cancer patients—the ‘Tor Vergata’ Observational study in oNCOlogy–TV-ONCO study”. M Schirru, **V Formica**, V Massimiliani, R Pellegrino, J Lucchetti, FR Antonetti, S Pellicori, S Riondino, M Roselli. **17th National Congress of Medical Oncology AIOM**, 23-25 October 2015, Rome, Italy
- (37) “Cisplatin plus capecitabine (CisCape) and concurrent pelvic radiotherapy for the neoadjuvant treatment of rectal cancer (RC)”. **V Formica**, L Martano, A Nardecchia, M Benassi, G Del Vecchio Blanco, E Giudice, E Mannisi, P Sileri, L Franceschilli, P Rossi, I Portarena, S Pellicori, E Krasniqi, R Adamo, S Riondino, R Santoni, M Roselli. **17th National Congress of Medical Oncology AIOM**, 23-25 October 2015, Rome, Italy
- (38) “A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix®) in combination with FOLFOX4

Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICO trial 0802". R Casaretti, P Comella, C Carlomagno, L Maiorino, E Greco, A Russo, G Sanna, ML Barzelloni, B Massidda, **V Formica**, C Serci, S Defraia, G Palmieri, MT Ionta. **17th National Congress of Medical Oncology AIOM**, 23-25 October 2015, Rome, Italy

- (39) "Nab-paclitaxel (nab-P) and gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): an Italian "real life" study". Guido Giordano, Antonio Febbraro, Vanja Vaccaro, Vittorina Zagonel, Ugo De Giorgi, Davide Melisi, Enrico Vasile, Roberto Bianco, G Lo Re, Monica Valente, **V Formica**, V Montesarchio, L Maiorino, G Sanna, A Bittoni, V Ricci, D Santini, A Zaniboni, M Milella, F De Vita. **European Cancer Congress ESMO 2015**
- (40) "Ideal Body Mass Index (BMI) is significantly different between curatively resected and metastatic colorectal cancer (CRC) patients on chemotherapy". **V Formica**, S Pellicori, HT Arkenau, C Morelli, J Lucchetti, A Nardecchia, S Riondino, P Ferroni, V Cereda, M Tesauero, F Guadagni, M Roselli. **European Cancer Congress ESMO 2015**
- (41) "Cisplatin plus capecitabine (CisCape) and radiotherapy (RT) for the neoadjuvant treatment of rectal cancer: final update of previously reported data". **V Formica**, L Martano, A Nardecchia, I Portarena, M Benassi, E Guidice, G Del Vecchio Blanco, E Mannisi, L Franceschilli, P Sileri, M Roselli. **ESMO 17th World Congress on Gastrointestinal Cancer**, 1-4 July 2015, Barcelona, Spain
- (42) "Ideal Body Mass Index (BMI) difference between curatively resected and metastatic colorectal cancer (CRC) patients on chemotherapy". **Vincenzo Formica**, Stefania Pellicori, Hendrik-Tobias Arkenau, Cristina Morelli, Jessica Lucchetti, Antonella Nardecchia, Silvia Riondino, Patrizia Ferroni, Vittore Cereda, Mario Roselli. **2015 ASCO Annual Meeting**
- (43) "Predictive Role of Neutrophil/Lymphocyte Ratio (Nlr) for Oxaliplatin Efficacy in Metastatic Pancreatic Cancer Patients (Pts)". **V Formica**, C Morelli, P Ferroni, A Nardecchia, M Tesauero, V Cereda, F Guadagni, M Roselli. **39th ESMO Congress (ESMO 2014)** Madrid, Spain 26 – 30 September 2014
- (44) "Systemic therapy in perivascular epithelioid cell tumors (PEComa)". N Hindi, R Sanfilippo, S Stacchiotti, E Fumagalli, M Libertini, S Provenzano, E Palassini, RM Bertulli, A Marrari, L Galli, **V Formica**, VE Chiuri, D Natale, P Collini, AP Dei Tos, PG Casali. **39th ESMO Congress (ESMO 2014)** Madrid, Spain 26 – 30 September 2014.
- (45) "CLINICAL IMPACT OF EUS–FNA ON DIAGNOSTIC WORK UP AND THERAPEUTIC DECISION IN PATIENTS WITH SUSPICION OF MALIGNANT LESIONS". E Mannisi, G Bevivino, M Coppola, S Romeo, OA Paoluzi, **V Formica**, I Portarena, P Sileri, F Pallone, G Del Vecchio Blanco. **20th National Congress of Digestive Diseases, Italian Federation of Societies of Digestive Diseases – FISMAD 2014**

- (46) "Peripheral CD45RO, PD1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab/5FU/irinotecan (B-FOLFIRI)". **V Formica**, V Cereda, MG Di Bari, I Grenga, M Tesauro, R Palmirotta, R Ferroni, F Guadagni, M Roselli. **ESMO European Cancer Congress 2013**
- (47) "Role of metastatic lymph node ratio as a prognostic index in colorectal cancer surgery". P Sileri, S D'Ugo, I Capuano, CI Ciangola, GP Angelucci, L Franceschilli, **V Formica**, F Perrone, N Di Lorenzo, AL Gaspar. **SICO Congress 2013**
- (48) "LEARNING CURVE FOR ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION (EUS-FNA) IN DIAGNOSIS OF ABDOMINAL AND MEDIASTINAL MASS". E Mannisi, A Caruso, M Coppola, V Formica, I Portarena, P Sileri, F Pallone, G Del Vecchio Blanco. **19th National Congress of Digestive Diseases, Italian Federation of Societies of Digestive Diseases – FISMAD 2013**
- (49) "Role of metastatic lymph node ratio as a prognostic index in colorectal cancer surgery".S D'Ugo, P Sileri, **V Formica**, L Franceschilli, M Roselli, GP Angelucci, M Capperucci, N Di Lorenzo, AL Gaspari. **SICO Congress 2012**
- (50) "The Influence of Prognostic Factors on Survival in Patients with Advanced Pancreatic Cancer Evaluated in not Referred Centre".Marta Cossignani, Anna Caruso, Manuela Coppola, Micaela Cretella, **Vincenzo Formica**, Ilaria Portarena, Francesco Pallone, Giovanna Del Vecchio Blanco. **ESMO 14th World Congress on Gastrointestinal Cancer 2012**, 27–30 June 2012, Barcelona, Spain
- (51) "Novel High-sensitive D-dimer Determination Predicts Chemotherapy-associated Venous Thromboembolism in Cancer Patients".P Ferroni, I Portarena, F LaFarina, G Massimiani, S Riondino, F Martini, S Mariotti, **V Formica**, F Guadagni, M Roselli. **22nd Biennial Congress of the European Association for Cancer Research 2012**, 7-10 July 2012 • Barcelona, Spain
- (52) "CONTRAST-ENHANCED ULTRASONOGRAPHY IN EARLY ASSESSMENT OF THE EFFICACY OF CHEMOTERAPY IN PATIENTS WITH LIVER METATASIS: A PRELIMINARY REPORT".Anna Caruso, Marta Cossignani, Micaela Cretella, Manuela Coppola, **Vincenzo Formica**, Ilaria Portarena, Mario Roselli, Francesco Pallone, Giovanna Del Vecchio Blanco. **ESMO 13th World Congress on Gastrointestinal Cancer 2011**, 22–25 June 2011, Barcelona, Spain
- (53) "CISPLATIN YIELDS HIGH RATE OF PATHOLOGIC COMPLETE RESPONSE (ypCR) IN COMBINATION WITH CAPECITABINE AND PELVIC RADIATION IN THE NEOADJUVANT TREATMENT OF RECTAL CANCER". **Vincenzo Formica**, Ilaria Portarena, Micaela Benassi, Valeria Fiaschetti,Giovanna Del Vecchio Blanco, Pierpaolo Sileri, Laura Martano, Cristiana Guidi,Luana Franceschilli, Francesco Pallone, Mario Roselli. **ESMO 13th World Congress on Gastrointestinal Cancer 2011**, 22–25 June 2011, Barcelona, Spain
- (54) "Metabolic Syndrome (MetS) in Metastatic (m) Colorectal Cancer (CRC) Patients (pts) Might Delay the Onset of Cachexia".

**Formica V, Grenga I, Tesauro M, Cereda V, di Bari MG, Guadagni F, Roselli M. 2011 ESMO European Multidisciplinary Cancer Congress**

- (55) "Ex-Vivo Intra-Arterial Methylene Blue Dye Injection Augments Pathology Lymph-Nodes Harvest Following Colorectal Cancer Surgery". Sileri P, Franceschilli L, D'Eletto M, Angelucci GP, Lazzaro S, Capperucci M, Palmieri G, Di Lorenzo N, **Formica V, Gaspari A. DDW 2011**
- (56) "Adhesional Small Bowel Obstruction After Open and Laparoscopic Colorectal Surgery: A Prospective Longer-Term Study". Sileri P, D' Ugo S, Franceschilli L, Angelucci GP, Capperucci M, Picone E, Gentileschi P, Di Lorenzo N, **Formica V, Roselli M, Gaspari A. DDW 2011**
- (57) "Metronomic capecitabine in advanced well or moderately differentiated neuroendocrine carcinomas". M Squadroni, G Di Meglio, F Spada, S Terzi, K Lorizzo, FG De Braud, **V Formica, A Goldhirsch, N Fazio. 2010 ASCO Annual Meeting**
- (58) "EUS ACCURACY IN RESTAGING RECTAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY: A PRELIMINARY REPORT". Caruso A, Blanco GDV, Cretella M, Mannisi E, **Formica V, Portarena I, Sica G, Sileri P, Roselli M, Gaspari A, Pallone F. XVI National Congress of Digestive Diseases - Italian Federation of Societies of Digestive Diseases - FISMAD 2010**
- (59) "VEGF polymorphisms as predictors of bevacizumab efficacy in metastatic colorectal cancer". **Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F, Roselli M. the EORTC – NCI – ASCO Annual Meeting on ‘Molecular Markers in Cancer’ 2009**
- (60) "Access Related Complications After Open and Laparoscopic Colorectal Surgery: A Prospective Study". Sileri P, D'Ugo S, **Formica V, Gentileschi P, Stolfi VM, Di Lorenzo N, Angelucci GP, Roselli M, Gaspari A. DDW 2009**
- (61) "Access Related Complications After Open and Laparoscopic Colorectal Surgery: A Prospective Study". Pierpaolo Sileri, Stefano D'Ugo, V Stolfi, **V Formica, P Gentileschi, Nicola Di Lorenzo, M Roselli, GP Angelucci, Achille Gaspari. XV National Congress of Digestive Diseases Italian Federation of Societies of Digestive Diseases - FISMAD 2009, 28 March-1 April 2009 • Milan, Italy**
- (62) "ROLE OF CIRCULATING TUMOUR MARKER CA19.9 AND ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER ON FIRST LINE SYSTEMIC TREATMENT". Blanco GD, **Formica V, Portarena I, Caruso A, Mannisi E, Massara M, Grenga I, Rossi L, Pallone F, Roselli M. XIV National Congress of Digestive Diseases 2008, Italian Federation of Digestive Diseases - FIMAD, 8-12 March 2008 • Rimini, Italy**
- (63) "Rectal cancer T staging: Role of endoscopic ultrasound (EUS) and computerized tomographic colonography (CTC)". Del Vecchio BG, Sileri P, **Formica V, Portarena I, Flori R, Vanni S, Varani S, Sica G, Palmieri G, Gaspari L, Simonetti G, Roselli M, Pallone F. ESMO International Symposium: 10th World**

- (64) "Role of circulating tumour marker CA 19.9 and antiangiogenic therapy with bevacizumab in patients with metastatic colorectal cancer on first line systemic treatment". **Formica V**, Portarena I, Fiaschetti V, Del Vecchio G, Massara M, Sica G, Sileri P, Grenga I, Pallone F, Roselli M. **ESMO International Symposium: 10th World Congress on Gastrointestinal Cancer 2008**, 25-28 June, 2008: Barcelona, Spain
- (65) "SERUM LEPTIN LEVELS IN COLORECTAL CANCER PATIENTS". Guadagni F, Roselli M, Spila A, D'Alessandro R, Lucci I, Polce L, **Formica V**, Laudisi A, Portarena I, Palmirotta R, Ferroni P. **EIGHTH INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH 2008**
- (66) "A NOVEL NONSENSE MUTATION IN KRAS GENE". Palmirotta R, Savonarola A, **Formica V**, Ludovici G, D'Alessandro R, Leone B, Ciancia M, Liberatore R, D'Angelo S, Roselli M, Guadagni F. **EIGHTH INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH 2008**
- (67) "ASSOCIATION BETWEEN INFLAMMATORY MEDIATORS, D-DIMER LEVELS AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN PATIENTS WITH ADENOCARCINOMA". Roselli M, **Formica V**, Martini F, Portarena I, Mariotti S, Del Monte G, La Farina F, Lucci I, D'Angelo S, Ferroni P, Guadagni F. **EIGHTH INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH 2008**
- (68) "Feasibility and efficacy of video-assisted home care for cancer patients on chemotherapy (medical care continuity-mcc project). the preliminary italian experience". M Roselli, **V Formica**, E Fossile, R Pellegrino, M Mari, M Rabuffetti, FR Benedetto, G Visconti, E Bollero. **ECCO 14: The European Cancer Conference 2007**, Barcelona 23-27 September 2007
- (69) "The prognostic role of the WHO classification, urinary 5-hydroxyindoleacetic acid (u5HIAA) and liver function tests (LFTs) in metastatic neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract". **Formica V**, Norman AR, Cunningham D, Wotherspoon A, Sirohi B, Oates J, Chong G. **2006 ASCO Annual Meeting**
- (70) "the new WHO classification for prognostic assessment of advanced neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract". **Formica V**, Norman AR, Cunningham D, Sirohi B, Chong G, Wotherspoon A, Rao S. **ASCO GI 2006**
- (71) "Metronomic oral chemotherapy (CT) versus the same regimen in association with Thalidomide (TLM): results of a randomized trial in patients (pts) with advanced breast cancer (ABC)". L Orlando, M Colleoni, F Bertolini, R Ghisini, G Sanna, **V Formica**, F Nolè, G Viale, L Franceschelli, A Goldhirsch. **2004 ASCO Annual Meeting**
- (72) "Antiangiogenic effects might correlate with clinical efficacy of very low doses of alpha-2b-Interferon combined with long acting release Octreotide in patients with metastatic neuroendocrine

carcinoma". Nicola Fazio, Aron Goldhirsch, Laura Zorzino, Andrea Rocca, Cristina Marengi, Sara Manzoni, **Vincenzo Formica**, Alessandra Balduzzi, Franco Nolè, Filippo De Braud. **AACR 2004**

- (73) "Imatinib discontinuation in patients with metastatic gastrointestinal stromal tumors (GISTs)". Tommaso de Pas, Roberto Biffi, Giovanni Mazzarol, Paolo Della Vigna, Laura Travaini, Giuseppe Curigliano, **Vincenzo Formica**, Filippo de Braud. **29th ESMO Congress 2004**, Vienna, Austria, 29 October - 2 November 2004
- (74) "A phase II trial to assess the efficacy and safety of gefitinib (Iressa™) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen". G Curigliano, O De Cobelli, MT Sandri, L Zorzino, C Noberasco, T De Pas, E Scardino, **V Formica**, S Manzoni, F de Braud. **16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2004** (16EORC-NCI-AACR), 28 September 2004 • Geneva, Switzerland
- (75) "Up-regulation of carcinoembryonic antigen (CEA) expression by staurosporine in circulating colon cancer cells". **Formica, V**; Prete, S; Massara, M; Graziani, G; Fossile, E; Bonmassar, E; Aquino, A .The **20th International Academy of Tumor Marker Oncology Conference 2003**. Tumor Marker in Cancer diagnosis and Therapy June 21-25, 2003, Siena, Italy

#### PRESENTAZIONI A CONGRESSI NAZIONALI

**Relatore** nel meeting "YO – IO ONCOLOGISTS IN IMMUNOLOGY 3.0" Roma – 11 novembre 2022

**Relatore** nel meeting: "MANAGEMENT DEL PAZIENTE BRAF V600E NEL CRC METASTATICO" Roma - 4 Novembre 2022

**Discussant** nel webinar "THIRD ITALY VS SPAIN HPBS WEBINAR -SURGICAL TREATMENT OF CHOLANGIOCELLULAR CARCINOMA" Webinar - 11 Aprile 2022

**Relatore** nel meeting: "CCA - COLORECTAL CANCER ACADEMY: COSTRUIRE IL SAPERE.2a EDIZIONE" Roma - 29 Aprile 2022

**Moderatore** nel meeting: "GESTIONE MULTIDISCIPLINARE DELLA PATOLOGIA BILIARE BENIGNA E MALIGNA: NUOVE EVIDENZE E STANDARD DI QUALITÀ" Roma - 8 Aprile 2022

**Moderatore** nel meeting "GESTIONE MULTIDISCIPLINARE DEL PAZIENTE IN NUTRIZIONE ARTIFICIALE E PRESA IN CARICO CONDIVISA TRA L'OSPEDALE E IL TERRITORIO" Roma - 4 Marzo 2022

**Relatore** nel meeting "AGGIORNAMENTI IN ONCOLOGIA. IL TUMORE DEL COLON RETTO: LE NOVITÀ DELL'ULTIMO ANNO" – Roma - 3 FEBBRAIO 2022



**Relatore** nel meeting “AIOM LAZIO. BEST OF THE YEAR 2021” – Roma - 3 DICEMBRE 2021

**Discussant** nel webinar “FIRST ITALY VS SPAIN HPBS WEBINAR - STRATEGIES FOR SURGICAL TREATMENT OF CRLM” – Webinar - 18 November 2021

**Relatore** nel meeting “COLON... IZZIAMOCI - TUTORSHIP SU CARCINOMA DEL COLON-RETTO METASTATICO” – Roma - 27 SETTEMBRE 2021

**Relatore** nel webinar “Open questions in metastatic colorectal cancer” webinar – 26 giugno 2021

**Relatore** nel meeting “Advisory Board. Algoritmo di trattamento del tumore del colon-retto metastatico Ras Wild Type: dalla prima alla terza linea” – Roma – 23 GIUGNO 2021

**Relatore** nel webinar “Open questions in metastatic colorectal cancer” webinar – 28 giugno 2021

**Relatore** nel webinar “CCA - COLORECTAL CANCER ACADEMY: COSTRUIRE IL SAPERE” webinar – 27 Aprile 2021

**Relatore** nel meeting “Tumori colorettali avanzati oltre la seconda linea: ipotesi di algoritmi decisionali. La realtà della regione Lazio” – Roma – 26 febbraio 2021

**Relatore** nel meeting “ONCOClass Clinical challenges in Oncology” – Roma – 18 febbraio 2021

**Relatore** nel meeting “Casi clinici nell'anticoagulazione: la gestione della FA” – Roma – 16 Gennaio 2021

**Relatore** nel meeting “VI CORSO ANNUALE TUMORI GASTROINTESTINALI: DALLA PRATICA CLINICA ALLA BIOLOGIA. Updates in research and practice in GI cancer” – Prato – 20 NOVEMBRE 2020

**Relatore** nel meeting “LA PERSONALIZZAZIONE DEL TRATTAMENTO NEL TUMORE DEL COLON” – Roma – 21 OTTOBRE 2020

**Relatore** nel meeting “2° Congresso di ONCOLOGIA DEI CASTELLI ROMANI” – Frascati – 29-30 Novembre 2019

**Relatore** nel meeting “Advances in gynecologic oncology” – Milano – 12 novembre 2019

**Relatore** nel meeting “UPDATE IN COLORECTAL CANCER” – Roma – 9 ottobre 2019

**Relatore** nel meeting “BEYOND Second line Therapy of COLORECTAL Cancer REfractory to standard therapy” – Bari – 21 settembre 2019

**Relatore** nel meeting “mCRC: key to the 2nd line” – Roma – 18 settembre 2019

**Moderatore** nel meeting “SEMINARIO MULTIDISCIPLINARE. SCREENING e DIAGNOSI PRECOCE del TUMORE della MAMMELLA e del PANCREAS

ASSOCIATO a MUTAZIONE GENETICA”– Roma – 10 Maggio 2019

**Relatore** nel meeting “MEMO: MERCK Oncology Meeting emotional experience”– Milano – 23 marzo 2019

**Relatore** nel meeting “1° Congresso di ONCOLOGIA DEI CASTELLI ROMANI”– Frascati – 1 Dicembre 2018

**Relatore** nel meeting “Gemma: GESTIONE DEL CARCINOMA METASTATICO DEL COLONRETTO CON ANTIANGIOGENICI”– Roma – 12 Novembre 2018

**Relatore** nel meeting “La Gestione del Paziente con mCRC”– Roma – 28 settembre 2018

**Relatore** nel meeting “UNA RIFLESSIONE TRASLAZIONALE SUL CARCINOMA DEL COLON RETTO OPINION LEADERS A CONFRONTO”– Roma – 27 settembre 2018

**Relatore** nel meeting “13° Congresso GIORNATE ONCOLOGICHE DEI CASTELLI ROMANI”– Frascati – 1/2 Dicembre 2017

**Relatore** nel meeting “MEDICI DEL FUTURO 2.0 FARMACI EQUIVALENTI-BIOSIMILARI QUALITÀ, EFFICACIA E SOSTENIBILITÀ” 22 NOVEMBRE 2017

**Relatore** nel meeting “Corso di Aggiornamento di SOUTHERN ITALY COOPERATIVE ONCOLOGY GROUP-ONLUS: ORIENTAMENTI TERAPEUTICI DOPO LA TERAPIA ADIUVANTE AL COSPETTO DEI NUOVI FARMACI”– Napoli – 11 Dicembre 2015

**Relatore** nel meeting “10° Congresso GIORNATE ONCOLOGICHE DEI CASTELLI ROMANI”– Frascati – 5/6 Dicembre 2014

**Relatore** nel meeting “Congresso Nazionale S.I.C.O.G.”– Cagliari, 13 e 14 giugno 2014

**Relatore** nel meeting “NUOVE FRONTIERE IN ONCOLOGIA: INTERAZIONE TRA CHIRURGO, ONCOLOGO E RADIOTERAPISTA”. Galatina – 8 Febbraio 2014

**Relatore** nel meeting “9° Congresso GIORNATE ONCOLOGICHE DEI CASTELLI ROMANI”– Frascati – 29 Novembre 2013

**Relatore** nel meeting “7° Congresso GIORNATE ONCOLOGICHE DEI CASTELLI ROMANI”– Frascati – 25 Novembre 2011

**Relatore** nel meeting “Gli oppioidi nel trattamento del dolore oncologico”– Rocca di Papa/Montecompati – 15 Giugno 2011

**Relatore** nel meeting “QUALITÀ DELL’ASSISTENZA NELLA GESTIONE DEL PAZIENTE ONCOLOGICO”– Roma 03 – 04 Marzo 2011, 25 – 26 Marzo 2011, 22 – 23 Aprile 2011

**Relatore** nel meeting “G Quadro – Roma. Quadro d’insieme sulla gestione del trattamento della neutropenia: impiego dei G-CSF”– Roma – 11 Giugno 2009

**Relatore** nel meeting “4° Congresso GIORNATE ONCOLOGICHE DEI CASTELLI ROMANI” – Frascati – 22 Novembre 2008

## ORGANIZZAZIONE CONGRESSI

**Organizzatore del congresso:** “APPROCCIO MULTIDISCIPLINARE AI TUMORI NEUROENDOCRINI (NET) GASTROINTESTINALI (GI)” Policlinico Tor Vergata - ROMA - 24 Gennaio 2020

**Organizzatore del congresso:** “Gestione multidisciplinare del TUMORE del COLON RETTO. Focus su instabilità microsatellitare, mutazioni BRAF ed altre mutazioni.” Webinar Live - ROMA - 23 Ottobre 2020

**Organizzatore del congresso:** “GLI ONCO-JOURNAL CLUB DEL POLICLINICO UNIVERSITARIO TOR VERGATA” Policlinico Tor Vergata, Aula Anfiteatro - ROMA - 9 Novembre 2022 e 7 Dicembre 2022

**Organizzatore del congresso:** “COLON... IZZIAMOCI. tutorship su carcinoma del colon-retto metastatico” - Starhotels Metropole - ROMA 27 Ottobre 2022

## ADVISOR IN ADVISORY BOARD

**Advisor** nel Board dal titolo “Training a field force – Riunione operativa settembre 2019”, ROMA - 11 settembre 2019

**Advisor** nel Board dal titolo “Analisi dei trend di utilizzo di bevacizumab: un focus sulla pratica clinica”, Milano - 20 dicembre 2018

**Advisor** nel Board dal titolo “mPaCa: disease and treatment management”, Roma - 20 giugno 2018

**Advisor** nel Board dal titolo “Erbitux nei pazienti mCRC RAS wt nella pratica clinica”, Roma - 21 maggio 2018

**Advisor** nel Board dal titolo “Expert Forum – The key to effective scientific presentations for clinical audiences” - Crowne Plaza Hotel Berlin - Potsdamer Platz” - 29 November 2016.

**Advisor** nel Board dal titolo “2014 Highlights: Impact of new data in 1st line in mCRC RAS WT patients” - Roma, 12 Dicembre 2014, SHERATON GOLF 2 PARCO DE' MEDICI HOTEL

**Advisor** nel Board dal titolo “2nd European Expert Board Meeting NORDIC” - September 27, 2014 - Madrid, Spain

## ATTIVITÀ COME REVIEWER E MEMBRO DI EDITORIAL BOARD

### Membro dell'editorial board di

- World Journal of Gastroenterology
- Frontiers in Gastroenterology

Regolare attività di Revisore indipendente di articoli scientifici per numerosi giornali indicizzati tra cui:

- British Journal of Cancer
- Journal of the National Comprehensive Cancer Network
- World Journal of Gastroenterology
- Clinical Colorectal Cancer
- Heart Failure Reviews
- Cancer Chemotherapy and Pharmacology
- Oncology
- Expert Opinion in Therapeutic Targets
- Tumor Biology
- Cancers
- Tumori Journal

### MERBERSHIP SOCIETÀ SCIENTIFICHE

- ESMO (European Society of Medical Oncology)
- AIOM (Associazione Italiana di Oncologia Medica)
- ASCO (American Society of Clinical Oncology)

### RICONOSCIMENTI

Vincitore del premio al merito MERIT AWARD al congresso ASCO GI 2006 per la ricerca dal titolo "the new WHO classification for prognostic assessment of advanced neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) tract" selezionato tra i 25 top-scoring abstract del congresso sottomessi da in-training doctors

*Il sottoscritto, VINCENZO FORMICA, nato a POLICORO, il 12-12-1976, DICHIARA CHE tutto quanto sopra dichiarato corrisponde a verità, ai sensi degli articoli 46 e 47 del D.P.R. 445 del 2000.*

In fedeRoma, 01/12/2022

Firma

